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ABSTRACT 
Douglas J Ball:  Medical Benefit of Preemptive Reporting of Pharmacogenomic Information from Whole 
Exome Sequencing 
(Under the direction of Jim Porto) 
 
The effectiveness of utilizing individual patient’s whole exome sequencing (WES) genetic 
information to influence patient care by predicting and preventing possible adverse drug reactions (ADRs) 
is investigated.  Pharmacogenomically relevant variants from WES studies collected into two databases 
were analyzed to determine the expected medical benefit of reporting the incidental findings when WES 
studies are performed.  One dataset was from UNC Chapel Hill as part of the NCGENES project 
database; the other was from Columbia University Medical Center’s Whole Exome Research Database.  
The frequency of possible drug exposure for individuals in the US population was approximated by using 
data gathered from a database of outpatient drug prescribing, www.imshealth.org using the new 
prescription number data for 2014.  Results were calculated to determine the aggregate number needed 
to screen (ANNS) to determine need for a change in medical management (different drug prescribing, 
monitoring, etc). 
The NCGENES data utilized in this analysis included data from 672 individuals’ genomes.  The 
projected ANNS for this data set was 54.02.  The calculated mean ANNS for the simulated data was 
54.11, with a 95% confidence interval from 53.94 to 54.30 using Monte Carlo simulation (based on 1000 
simulated points).  CUMC data utilized in this analysis included data from 2,983 individuals’ genomes. 
The projected ANNS for this data set was 46.15.  Using Monte Carlo simulation, the calculated mean 
ANNS was 46.00 and the projected 95% confidence interval was from 45.93 to 46.08.  Monte Carlo 
simulation of the error in these values was used to compute a 95% confidence interval, because of the 
complexity of estimating errors in these calculations. 
Based on this analysis, the pharmacogenomically relevant impact of using WES based screening 
is in the range of 46 to 52 persons needed to screen when using incidental findings to dictate an expected 
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change in management.  A model implementation plane for incorporating pharmacogenomic information 
into patient care within a healthcare system is provided and discussed 
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CHAPTER 1: TOPIC AND INTRODUCTION 
 
It is estimated that more than two million adverse drug reactions (ADRs) occur annually in the 
United States of America, resulting in over 100,000 deaths.1  The number of ADRs is similar to the 
number of preventable medical errors that occur annually in the United States.  However, unlike medical 
errors, ADRs are not currently considered to be preventable.  Instead they are considered to be an 
unavoidable consequence of the practice of medicine.  Evidence is mounting, however, that ADRs may 
not be unavoidable and are due partly to individual genetic variation.2 
Herein the effectiveness of utilizing individual patient’s genetic information to predict and prevent 
possible ADRs and treatment failures will be investigated.  The field involving the study of the impact of 
individual genetic variation on drug therapy is generally known as either “pharmacogenetics” or 
“pharmacogenomics.”  This is an application of pharmacogenomics to patient care. This strategy is an 
alternative to the existing “one-drug-fits-all” approach to drug treatment.  Although pharmacogenomics 
does not account for 100% of variability in drug response or adverse events, it is clear that certain specific 
genetic variants significantly affect outcomes of certain drug therapies.   
The extremely rapid growth of knowledge in genetics has become a key feature of what has now 
been labeled as the “post genomic era.”  As a part of this, the clinical utility of this expanding knowledge 
of individual patient’s genotypes has also been increasing rapidly.  Whole Exome sequencing (WES) to 
aid in the diagnosis of genetic diseases has recently become available as a clinical tool for routine use in 
the United States.  WES is a medical test in which all 20,000+ genes in the human genome are 
sequenced using what is now often termed next-generation sequencing.3  WES is typically used to 
answer specific diagnostic questions, which are the focus of the report generated by laboratorians for the 
requesting clinicians. 
One of the byproducts of such analysis is the sequencing of genes associated with the individual 
patient’s potential response to drugs.  WES is done for reasons other than pharmacogenomic evaluation, 
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and while pharmacogenomically important genes are sequenced, they are neither analyzed nor reported 
in most cases.  The sole exception to this is a gene that is known to mediate malignant hyperthermia: 
RYR1 which is a member of a group of 56 high consequence genes that are typically reported as 
incidental finding that will be discussed in greater detail in Chapter 24.  Although the percentage of 
patients undergoing WES is currently relatively small, this number is expected to increase as sequencing 
costs continue to decline.  Thus, the amount of genetic data generated from WES, and available for 
analysis and reporting, is expected to also rapidly expand.    
Here, pharmacogenomically relevant variants from WES studies have been analyzed to 
determine the expected medical benefit of reporting the information when WES studies are performed.  
Two research databases of WES results were searched for pharmacogenomically significant variants, 
and population level data regarding drug utilization and drug-variant pair risk were used to create a model 
of clinical impact of variant reporting; one database was from UNC Chapel Hill and the other from 
Columbia University. 
The researchable question is as follows: 
What is the expected medical benefit of reporting incidental findings of pharmacogenomic 
significance from whole exome sequencing studies? 
This analysis will require that the findings that meet standards of “pharmacogenomic significance” 
be determined.  Significance will be decided by determining which pharmacogenetic variants are clinically 
actionable; these criteria are detailed in the methods section.  Expected medical benefit will be reported 
as a predicted Number Needed to Screen (NNS), based on the frequency of clinically actionable 
pharmacogenomics variants in the WES patient population and the chance of drug exposure.  Because 
genetically mediated risk in an individual depends both on the presence of a pharmacogenomically 
important variant, and the likelihood that the individual will be exposed to a drug for which that variant is 
important, a method of predicting the likelihood of relevant drug exposures will also be required.  For this 
purpose, drug prescribing information, compiled from the general population of the United States, will be 
used.   
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Because of the complexity of implementing the use of such pharmacogenomics information in the 
healthcare system, a model implementation plan is provided and discussed. This implementation plan 
addresses the incorporation of this information into both the electronic health record (EHR) and the 
clinical decision support (CDS) system, based on current clinical informatics best practices. 
To summarize, the key elements to be addressed are the following: 
 Identifying and using timely sources of genetic information and pharmacogenomics knowledge; 
 Modeling the clinical benefit of reporting incidental pharmacogenomics findings from WES; 
 Presenting a model implementation plan for preemptive pharmacogenomics based on current 
clinical informatics best practices. 
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CHAPTER 2:  LITERATURE REVIEW AND BACKGROUND 
 
Genomic technology is developing at a breathtaking rate, and has the potential to change the way 
medicine is practiced in a variety of ways, bringing great opportunity while presenting multiple challenges.  
Several technologies have converged to provide the ability to compile large amounts of genetic and 
genomic information, which can then potentially be used in the care of the patient.   The implementation 
of pharmacogenomics, however, is difficult because genetic testing and analysis is optimally done and 
results returned to the clinician before drugs are prescribed.  This requires both that the provider is 
knowledgeable about pharmacogenomics, and that this patient-specific genomic information is available 
before the prescription is written.  The clinical implementation of this “preemptive” testing strategy 
synthesizes knowledge from public health screening, next generation sequencing, and clinical 
informatics.   
As with many health innovations, the utility of pharmacogenomics interests clinicians and 
scientists alike.  Cohen reviewed and summarized the key values of pharmacogenomics to be 1) to 
decrease adverse drug reactions; 2) to optimize treatments based on a patient’s unique genotype; 3) to 
enhance drug discovery; and 4) to improve efficacy trials.5  Even though the cost of implementing any 
new technology is a concern, integrating pharmacogenomic information into pharmaceutical discovery 
pipelines should in theory reduce the cost of bringing drugs to market.6 
In support of this proposed research and implementation plan, four broad areas of inquiry are 
particularly relevant.  The first is the clinical benefit of pharmacogenomically informed prescribing, the 
second is access to pharmacogenomics knowledge, the third is the reporting of incidental findings 
produced by next generation sequencing assays, and the fourth is the implementation of 
pharmacogenomics into clinical practice.   
By its very nature, pharmacogenomics involves the interactions and consequences of specific 
drugs with a specific gene (or sometimes a set of genes). The literature has many examples of specific 
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drug-gene pairs that are given to illustrate the broad concepts involved in pharmacogenomics, and how 
this discipline might change the delivery of care.   
Common examples include Thiopurine and TPMT; Codeine and CYP2D6; and the interactions of 
Warfarin and the pair of genes VKORC1 and CYP2C9.   The thiopurine methyltransferase (TPMT) gene 
has an impact on thiopurine therapy for acute lymphoblastic leukemia; TPMT pharmacogenomics can be 
used to identify patients at high risk of hematopoietic toxicity after thiopurine therapy.7,8  Another often 
discussed gene is the hepatic cytochrome P450 gene CYP2D6, which is involved with the metabolism of 
many pharmaceutical agents. The impact of the CYP2D6 genotype or phenotype on the metabolism of 
codeine, a drug used for pain management, is often described.  CYP2D6 polymorphisms affect both the 
effectiveness and safety of Codeine, and may dictate dose adjustments or choice of an alternate drug.8,9 
 Variation in drug effectiveness can also be influenced by genetic variation in drug receptors: a 
common example of this is variance in the molecular target of warfarin (the vitamin K-epoxide reductase 
protein), encoded by the gene VKORC1, which strongly influences the dose levels required by individual 
patients.10  In 2005 it was demonstrated that, although neither VKORC1 nor CYP2C9 genotypes 
separately were effective predictors of interpatient variation in response to warfarin, the VKORC1 
genotype together with the CYP2C9 genotype explained many differences in the response to treatment.11  
For all these drug-gene pairs, testing for the implicated genetic variant prior to drug prescribing might 
improve the safe and effective use of the drug (or use of a different drug if needed). 
There is a growing body of literature looking at drug metabolism and response as a function of 
pharmacogenomic variants.  Studies of pharmacogenomic response in twins have shown that in general 
between 20% and 95% of an individual’s drug response is determined by genotype.12  A systematic 
review in 2001 looked at drugs commonly implicated in adverse reactions, and concluded that knowledge 
of the genetic variants that lead to poor metabolism may guide prescribing that reduces adverse 
outcomes.2  A systematic review in 2005 showed that there is good evidence of how genotypes influence 
drug prescribing, but “the “crucial data for assessing the value of Pharmacogenomics with regard to its 
impact on clinical practice and outcomes are currently lacking”.13   Since this time, pharmacogenomics 
knowledge has expanded, the number of reports in the literature has increased, and the focus has shifted 
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to improving outcomes and reducing harmful events.  In 2014, Su et al reviewed the pharmacogenomic 
determinants of adverse drug reactions (ADRs) and summarized the state of progress.14  They concluded 
that “thousands of genetic variations that are associated with drug safety and toxicity have been 
identified, many of which have shown high accuracy at predicting drug responses and adverse events.”   
However, despite the growing evidence for the role of pharmacogenomics in clinical care, use 
remains limited to specific instances of drug-gene pairs, and to a small number of centers nationally.  In 
2015, Dunnenberger HM, Crews KR, Hoffman JM, et al. documented the experience of five centers 
implementing preemptive pharmacogenomic testing, and concluded that over 98 percent of patients have 
at least one high-risk pharmacogenomic diplotype.15  The work of these centers addresses the problems 
faced by pharmacogenomics; limited data on the utility of broad implementation of pharmacogenomics, 
and many barriers to implementation within patient care settings.  More evidence of clinical utility and 
improved outcomes is needed to further the progress in this field. 
Finding direct measures of utility in medicine can be challenging. One approach to the 
measurement of utility that has proved effective for public health screening is the number needed to treat 
(NNT), a concept published by Lapacus et al in 1988.16  The NNT is the number of patients needed to 
treat to prevent one adverse case: it is the reciprocal of the absolute risk reduction due to a treatment or 
screening test.  Absolute risk reduction is the difference in event rates between a control group and a 
screened or treated group.   When used for a public health screening program, the reciprocal of the 
absolute risk reduction is often called the number needed to screen (NNS) rather than the number need 
to treat (NNT).17 
Part of the application of a complex and rapidly changing body of knowledge is accessible and 
reliable sources of information that are adaptable and have been frequently updated to be relevant and 
safe.  Thus, a key element to the adoption of pharmacogenomics into practice is the need to have 
continually updated knowledge databases in the field.  Sources of information about pharmacogenomics 
that will be utilized in this dissertation include PharmGKB with its ranking of Very Important 
Pharmacogenes, the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for 
7 
 
prescribing based on gene variants, and the FDA guidance for Pharmacogenomic Biomarkers in Drug 
Labeling. 
Initially developed as a research collaboration tool, PharmGKB is a centralized knowledge 
sharing site to facilitate data sharing which gives investigators with complementary data the ability to 
combine data sets.  PharmGKB is facilitating the clinical implementation of pharmacogenomics, as 
curators also construct clinically relevant summaries of variant-drug associations.18  Because of the 
quality of knowledge regarding these variants, they serve as a conservative set of variants for the 
exploration of the value of pharmacogenomics in our setting.   
PharmGKB is a partner in the Clinical Pharmacogenetics Implementation Consortium.19,20 CPIC 
guidelines are designed to help clinicians understand how available genetic test results should be used to 
optimize drug therapy, rather than which tests should be ordered. 21  These Clinical Practice Guidelines 
will also be used to guide analysis of the clinical significance of variants. 
The most heavily reviewed and curated drug information is available from the FDA.  The FDA has 
developed a list of Pharmacogenomic Biomarkers in Drug Labeling.   According to their website, FDA 
drug labeling information can include: “Drug exposure and clinical response variability, risk for adverse 
events, genotype-specific dosing, mechanisms of drug action, and polymorphic drug target and 
disposition genes.”22  FDA labeling as it pertains to pharmacogenomic information may appear in several 
locations in the package insert, including Warnings and Precautions, Contraindications, Boxed Warnings, 
and Adverse Reactions.23,24 Some, but not all, of the products have labeling that includes specific actions 
to be taken based on the biomarker information.   
As pharmacogenomics information becomes more widely available, and the knowledge to direct 
its use becomes more accessible to a broader set of providers, how to obtain and to use this genetic 
information becomes important.  One way of getting pharmacogenomics information is to order specific 
genetic tests or gene panels to determine a patient’s genotype and phenotype before prescribing certain 
drugs.  As an example, preemptive TPMT genotyping prior to thiopurine treatment initiation in children 
with acute lymphoblastic leukemia has been recommended, and has been shown to be cost effective.25  
Another example is checking VKORC1 genotype together with CYP2C9 genotype before prescribing 
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Coumadin.  Even though prior testing may decrease length of stay and cost over traditional dosing 
regimens, the cost of testing and delay in getting results limits the benefits.  
Another way to get pharmacogenomics information in advance of prescribing decisions is to 
enhance access to genetic information from the expansion of genome and whole exome sequencing.  
The American College of Medical Genetics and Genomics has noted that with clinical exome and genome 
sequencing, there is a potential for the “recognition and reporting of incidental or secondary findings 
unrelated to the indication for ordering the sequencing, but of medical value for patient care.”  The term 
“incidental findings” or “secondary findings” refers to genetic variants that are those other than what the 
test was ordered for, which are termed “diagnostic findings” or “primary findings.”  Incidental findings can 
be further subdivided into “Unintended” (e.g. Huntington’s disease), “Screening” (which include 
pharmacogenomic findings and risk alleles), and “Uninformative” (includes Variants of Unknown 
Significance). 
In May 2012, the American College of Medical Genetics and Genomics issued a 
recommendations statement suggesting incidental reporting of 56 genes, with pre-test consent of the 
patient.4  These recommendations have been criticized because of the uncertainty about the penetrance 
and scope of expressivity for many of the genes.  In addition, critics have pointed out a lack of clarity in 
clinical utility, as well as ethical questions about not providing the option to decline incidental reporting 
when undergoing testing.26,27   Although the debate about the clinical utility and ethics of reporting 
incidental findings is ongoing, with only a single exception, the 56 genes recommended by the American 
College of Medical Genetics and Genomics are not considered to be pharmacogenes.  Only one of these 
is specifically on the list as a pharmacogene due to its impact on drug prescribing, although several 
others may have implications for drug use in addition to other clinical recommendations.  An example is 
long QT syndrome, where in addition to recommendations to avoid drugs which prolong the QT interval, 
other medical and behavioral recommendations are associated with the genetic variant. 
Recommendations for reporting of incidental findings are predicated on an understanding of what 
to do with the results.  Berg et al looked at incidental findings, and categorized the results as follows: 
Clinically Actionable, Clinical Valid but not Actionable, and Uninformative.  Pharmacogenomic variants in 
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this scheme were categorized as being clinically valid but not actionable, because the risk to patients only 
occurs with treatment by a specific drug, which may never be prescribed.28  However, for some 
pharmacogenomics variants, or very commonly prescribed drugs, the utility of reporting these findings 
should be linked to the act of prescribing these drugs.  This is because the risk of adverse events in 
persons with these specific Pharmacogenomics variants is high, in some cases life- threatening.  As an 
example, children who are ultrarapid metabolizers of codeine can be given a life-threatening dose if their 
status is not known, because they immediately metabolize codeine to morphine resulting in toxic levels of 
this opioid.  Thus, for those patients exposed to that specific drug, this “incidental finding” goes from 
clinically irrelevant, to critical to avoid over-dosing of the drug.  The concept of providing 
pharmacogenomics information as a precursor to drug prescribing in certain susceptible individuals sets 
the stage for a discussion of how to incorporate available pharmacogenomic information into the medical 
record in a way that will inform safe drug prescribing. 
There is growing evidence for the clinical benefit of preemptive genomic testing prior to 
pharmaceutical prescribing, to guide decision making.  Preemptive testing is particularly useful when 
implemented with informatics tools such as clinical decision support within a broader program.   Using the 
combination of incidental findings from WES with preemptive pharmaceutical prescribing has not been 
described in the literature, with the exception of the single pharmacogene recommended by the ACMG 
for incidental reporting.  Delineating the clinical benefit of pharmacogenomics, particularly preemptive 
pharmacogenomics, in combination with the issues around the reporting of pharmacogenomics variants, 
and an understanding of the need for point-of-care information and decision support, are all important 
aspects of the implementation of pharmacogenomics into the healthcare system.    A more detailed 
discussion of the literature as it applies to such implementation can be found in Chapter 5: Model 
Implementation Plan.  
10 
 
 
 
 
CHAPTER 3: METHODS 
 
Pharmacogenomic knowledge is evolving at a rapid pace.  For the purpose of this work, the 
guidelines and recommendations current as of July 1, 2016 were used.  While it is certain that these 
guidelines will evolve over time, it is necessary for a thoughtful analysis.   The reader should keep this in 
mind. 
DATA SOURCES 
 
Two different whole exome sequence databases were analyzed; both of these databases were 
developed with other research in mind and were made available for this work.  The first was from UNC 
Chapel Hill as part of the NCGENES project database; the other was from Columbia University Medical 
Center’s Whole Exome Research Database.  UNC Chapel Hill IRB exemption was provided to this project 
for both data sets after application for review.  In addition to these two data sets, information about allele 
frequencies was obtained from PharmGKB (www.pharmgkb.org).  This is a website with curated genomic 
information and summaries of allele and genotype frequencies based on compiled literature.  This allele 
and genotype frequency information was used to represent the general population.  In addition, curated 
allele frequency data from the 1000 Genomes project was used to generate control values for 
comparison, when PharmGKB data were lacking.  This database was selected because of usability.  
Importantly, the NCGENES project data, and Columbia University Whole Exome data differ from those 
taken from PharmGKB and the 1000 Genomes project.  The latter curated data sets represent the best 
available data, using all methodologies (especially PharmGKB) and with techniques optimized for 
analyzing pharmacogenes and their complex allele variants.   Some of these variants have not been 
captured in the convenience samples from NCGENES and Columbia University Medical Center, which 
used more general sequencing protocols that were not optimized for this purpose.  These two samples 
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and the population data were used for comparison calculations, to help to determine the gap between 
incidental findings from WES, and the expected results based on current scientific knowledge. 
  NCGENES CUMC PharmGKB 
# of participants  672 2,983  Variable; aggregate 
data from many 
sources 
Population Adult and pediatric 
patients at University of 
North Carolina 
hospitals 
 Adult and pediatric 
patients at Columbia 
University Medical 
Center Hospitals 
International; variable, 
aggregated from peer-
reviewed literature on 
PGx 
Type of test Whole exome 
sequencing 
Whole exome 
sequencing 
Multiple; real-time 
Polymerase Chain 
Reaction (PCR), 
microarray technology 
(gene chip) 
Intent of test Diagnostic and 
research exomes.   
Not obtained for PGx 
purposes. 
  
Diagnostic and 
research exomes. 
Not obtained for PGx 
purposes. 
 
Pharmacogenomic 
testing 
TABLE 1:  COMPARISON OF DATA SOURCES. 
 
A list of clinically actionable variants was compiled, based on drug-gene pairs that have CPIC A 
status or Clinical Guidelines.  Also included were any drugs with FDA labeling of Actionable, Genetic 
Testing Required, or Genetic Testing Recommended from the FDA Table of Pharmacogenetic Markers in 
Drug Labeling.    The list of drugs with FDA labeling pertaining to pharmacogenomics, and the labeling 
excerpts and CPIC levels are listed in Appendix A.  Appendix B has the drug and CPIC guideline 
information. 
A useful concept in pharmacogenomics is that of “drug-gene pairs”; these are the combination of 
a specific gene and a specific drug that is a reason for concern due to potential risk, or possible need for 
modification of clinical care. However, simply knowing the gene in which a variant occurs is often not 
enough for this analysis.  There often are several distinct variants within a given gene that have different 
implications for the same drug, and whether an individual has one or two of variants is also sometimes 
important.  So in this analysis the term drug-genotype pair will be used to reflect this complexity.   
Appendix C has drug-gene pairs, based on the list of drugs in Table 1.  Appendix D is the table of allelic 
variant combinations that was used to predict phenotype/gene function. 
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To determine the likelihood that a hypothetical individual might have a gene variant that would be 
important in his or her healthcare, both the chance that the individual has the gene variant and that 
chance that the individual is exposed to an impacted drug must be determined (in the general population) 
for each variant.  This frequency of drug exposure for individuals in the US population was approximated 
by using data gathered from a database of outpatient drug prescribing, www.imshealth.org.  This has 
been provided for the drugs of interest for the United States.  This data includes TRX, the total 
prescription number data, and NRX, the new prescription number data for 2014.  NRX is used for the 
projected new exposures to medications, though it should be noted that for certain drugs with chronic use 
it may overestimate the true naive exposures rate because while refills are not captured as part of NRX, 
all new prescriptions are, even if the patient is already on that medication.  In addition to population level 
data on frequency of drug exposure, population level data on allele frequencies was also used as a 
comparison and for further analysis.    
The list of drugs that was requested from IMS health is below in table 2. 
abacavir Fluorouracil Sertraline 
allopurinol Fluvoxamine Simvastatin 
amitriptyline Imipramine Succinylcholine 
aripiprazole Irinotecan Sulfasalazine 
atomoxetine Ivacaftor Tacrolimus 
azathioprine mercaptopurine Tamoxifen 
boceprevir methylene blue propafenone 
capecitabine nitrofurantoin protriptyline 
carbamazepine norfloxacin rasburicase 
celecoxib nortriptyline Ribavirin 
chloroquine oxycodone Telaprevir 
citalopram paroxetine tetrabenazine 
clomipramine peginterferon alfa-2a thioguanine 
clopidogrel peginterferon alfa-2b thioridazine 
clozapine phenytoin Tramadol 
codeine primaquine Trimipramine 
dapsone probenecid Voriconazole 
desipramine propafenone Warfarin 
doxepin protriptyline  
escitalopram rasburicase  
esomeprazole Ribavirin  
TABLE 2: LIST OF DRUGS FOR WHICH DATA WAS REQUESTED FROM THE IMS HEALTH FOUNDATION 
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For each drug, there are known allelic variants in pairs for genotypes of pharmacogenomic 
significance.  Genotypes for each combination of alleles were calculated; then the genotypes (and 
corresponding phenotypes) were evaluated for recommended clinical actions.  These actions vary based 
on the genotype and corresponding phenotype, and may include: 
1. Dose adjustment 
2. Monitoring of clinical response (i.e. depression or pain) 
3. Monitoring of serum drug levels (i.e. imipramine) 
4. Monitoring of labs (i.e. Creatine Kinase or Liver Function Tests) 
5. Drug discontinuation or use of an alternative agent  
6. Targeted drug use (i.e. ivacaftor) 
The following information was reported for the data sets from NCGENES and Columbia University 
Medical Center: 
1. The number of Whole Exome Sequences used in the analysis. 
2. Frequency of patients with clinically actionable genotypes, based on drug-gene pairs.  
3. Likelihood of indicated clinical action with each specific drug based on phenotype. 
Allele frequencies were obtained for ancestry groups that most closely represent Whites, Blacks, and 
Asians in the United States.  These ancestries were classified slightly differently depending on the 
database (and original research population). The 1000 genome project has population data for African 
Ancestry in the Southwest US, East Asian ancestry, and Utah residents with Northern and Western 
European ancestry.  PharmGKB refers to these same ancestry groups as Caucasian (excluding 
European), African American, and East Asian.  Note that these groups are considered useful surrogates 
for the larger population of Whites, Blacks, and Asians in the United States.  U.S. Censes population data 
were used to race adjust these allele frequencies based on ethnic groups for the general US population 
(www.census.gov).  The U.S. Census year of 2015 was used; at that time the US total population was 
321,418,820.  Proportionally, Whites were 77.01% of the population, Blacks or African Americans were 
13.26%, and Asians were 5.6%.  The other races that were not used in this calculation due to lack of 
genetic data were American Indian, Alaskan Native, Native Hawaiian and other Pacific Islander, and 
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those with two or more races represented.  Together these groups represent <5% of the population of the 
United States. 
ANALYTICAL METHODS 
 
This data were used to derive a mathematical model that generated the expected need for 
change in clinical care based on a projected Number Needed to Screen (NNS).  The Number Needed to 
Screen was calculated for the NCGENES data set, the Columbia University data set, and for the general 
population of the U.S. based on published allele frequencies.  This result is reported as a composite NNS 
for all drug-gene pairs for NCGENES and for the Columbia University Medical Center data.  The predicted 
NNS for the entire United States population was also calculated as a population-based estimate using 
published allele frequencies. 
For a population with genotype-related adverse event frequency a and non-genotype-related 
adverse event frequency c, the following two by two table applies. 
 
TABLE 3: TWO BY TWO TABLE DEPICTING COMPONENTS OF POPULATIONS EXPOSED TO A SPECIFIC DRUG WITH A SPECIFIC 
PHARMCOGENE VARIANT 
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Rather than calculating only the NNS for one drug-gene pair, a NNS applying to all drug-gene 
pairs at once is required.  To accomplish this task, an aggregate number needed to screen (ANNS) is 
proposed.  Like the NNS above, this is the reciprocal of the ARR, however, in this case it is the aggregate 
absolute risk reduction (AARR).  The relative risk reduction is defined for individuals with a specific drug-
genotype combination.  This needs to be accounted for in the aggregate absolute risk reduction and 
aggregate number needed to screen.  For the multiple drug-gene pairs, the aggregate absolute risk 
reduction is given by: 
 
Where di is the risk of having a drug exposure and gi having the corresponding genotype. Then, 
 
And,  
Confidence intervals for the projected ANNS were also calculated.  A confidence interval for the 
ANNS could be obtained by taking reciprocals of the values defining the confidence interval for the 
aggregate absolute risk reduction. 
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The standard error for the absolute risk reduction for a single drug-genotype pair is given by,29 
 
Using the general equation of orthogonal standard error,29 Statistic ± 1.96 SEstatistic, the 95% 
confidence interval for the absolute risk reduction is given by ARRi+1.96SEi to AARR-1.96SEi 
And by back substitution, the confidence interval for the ANNS is given by the reciprocal of this interval, if 
di, and gi are assumed to have only small errors, as follows: 
 
However, it is hard to generalize about the precision in which di, and gi are known in our data 
sets, and the error in these coefficients may be significant.  Also, because we are relying on multiple 
studies in the literature for these data (as collected and curated by PharmGKB), SEi is not available for all 
drug-genotype pairs.  For these reasons Monte Carlo simulation has been employed to analyze the 
sensitivity of the 95 percent confidence interval errors in these values.30   
While it was an initial hope that an aggregate ARR for different adverse events could be 
computed, such detailed data were not available for all the terms in the calculation and that goal was 
abandoned based on the available literature.  Instead only the question of whether a change in clinical 
management was indicated based on genotype was addressed.  For this analysis the ARR is taken as 1, 
which makes the error contributed from the ARR term trivial.  However, the error contributed from the 
genotype frequency, and the drug exposure risk are neither clearly available in the literature for each drug 
gene pair, nor in our data sets, nor analytically straightforward to determine.  
When considering the chance of having a specific allele or pair of alleles, the binomial distribution 
describes the chances.  This is also the case when considering if a drug exposure occurs or not.  In both 
of these instances standard error can be described in terms of p (the chance of having or not having an 
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exposure or a drug), and N (the number of observations).  For genotype, the N needs to be multiplied by 
2 because of there are two alleles typically per observation. 
The binomial standard error is then given by, 
𝑆𝐸 = √
𝑝(1 − 𝑝)
𝑁
 
Because for genotype observations there are 2N allele observations for N subjects the binomial standard 
error is given by, 
𝑆𝐸 = √
𝑝(1 − 𝑝)
2𝑁
 
Unfortunately, the number of observations, N, is not available for all curated data for the allele 
frequencies from PharmGKB, however, approximate values are available that can serve to bound the 
standard error from above. 
Because of the complexity of the product of these errors for each term in the ANNS calculation, 
and the uncertainty in these values, Monte Carlo simulation of the error in these values was used to 
compute a 95% confidence interval for the ANNS.  For those parameters which a standard deviation is 
known, it is utilized in the Monte Carlo simulation; for those in which it is not known, the methodology of 
determining the plausible range of each variable outlined by Peter Muennig is empolyed.31 
When the parameter is based on an assumption or expert opinion it is tested over a very broad 
range of values.  Expert opinion is also used to determine plausible high and low values when available.   
When the parameter is obtained from a random sample, the 95 percent confidence interval for the 
parameter is used.    
The mathematical model and numerical simulation was conducted using a licensed copy of 
SAS9.4 .  The program code is provided as Appendix E, F and G.   
Results for CUMC and NCGENES data sets were confirmed by replicating the calculations using 
Excel which excluded the Monte Carlo simulations. 
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CHAPTER 4: RESULTS 
 
The Pharmacogenomics data from FDA drug labels and CPIC A guidelines were reviewed.  
There were a total of 48 drugs that met our criteria; 38 had pharmacogenomic information on the FDA 
label, 46 had CPIC A levels, and 30 had both.   
 
 
 
 
 
 
 
FIGURE 1: A VENN DIAGRAM DEPICTING OVERLAP BETWEEN CPIC CATEGORY A DRUGS AND DRUGS WITH 
PHARMACOGENOMICS INFORMATION ON FDA LABEL. 
 
The results of the drug request from IMS Health are below: the table has the drug name and the number 
of new prescriptions for the year 2015 nationally.
Drug Name New RX # 
ABACAVIR 44080 
ALLOPURINOL 6192623 
AMITRIPTYLINE 6170974 
ARIPIPRAZOLE 4747675 
ATOMOXETINE 1313449 
AZATHIOPRINE 676708 
BOCEPREVIR 303 
CAPECITABINE 86800 
CARBAMAZEPINE 1842873 
CELECOXIB 4003495 
CHLOROQUINE 66824 
CITALOPRAM 15433189 
CLOMIPRAMINE 192397 
CLOPIDOGREL 8620060 
CLOZAPINE 749014 
CODEINE 76869 
DAPSONE 717082 
DESIPRAMINE 118670 
DOXEPIN 1301955 
ESCITALOPRAM 12901839 
ESOMEPRAZOLE 5723341 
FLUOROURACIL 722640 
FLUVOXAMINE 509629 
IMIPRAMINE 444363 
IRINOTECAN 724 
IVACAFTOR 1037 
MERCAPTOPURINE 189240 
METHYLENE BLUE 59 
NITROFURANTOIN 8100477 
PHARMACOGENOMICS 
on FDA label = 38
CPIC A = 46
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NORFLOXACIN 2550 
NORTRIPTYLINE 1773482 
OXYCODONE 23283753 
PAROXETINE 6501057 
PEGINTERFERON 
ALFA 2A 
17553 
PEGINTERFERON 
ALFA 2B 
4560 
PHENYTOIN 1737817 
PRIMAQUINE 3414 
PROBENECID 80691 
PROPAFENONE 264793 
PROTRIPTYLINE 19969 
RASBURICASE 6 
RIBAVIRIN 65958 
SERTRALINE 19036779 
SIMVASTATIN 24523203 
SUCCINYLCHOLINE 169 
SULFASALAZINE 541140 
TACROLIMUS 808518 
TAMOXIFEN 551094 
TELAPREVIR 251 
TETRABENAZINE 4043 
THIOGUANINE 1878 
THIORIDAZINE 76088 
TRAMADOL 30859928 
TRIMIPRAMINE 1805 
VORICONAZOLE 37999 
WARFARIN 16437806 
TABLE 4: IMS HEALTH FOUNDATION DRUG DATA FOR THE UNITED STATES IN 2014 
 
The drugs were sorted by frequency of prescribing; the following are the 10 most commonly 
prescribed drugs with pharmacogenomic significance in the United States in 2014.  
Drug Name # New Rx Frequency 
TRAMADOL 30859928 14.9 
SIMVASTATIN 24523203 11.8 
OXYCODONE 23283753 11.2 
SERTRALINE 19036779 9.17 
WARFARIN 16437806 7.92 
CITALOPRAM 15433189 7.43 
ESCITALOPRAM 12901839 6.22 
CLOPIDOGREL 8620060 4.15 
NITROFURANTOIN 8100477 3.9 
PAROXETINE 6501057 3.13 
 
TABLE 5: TEN MOST COMMON DRUGS FROM THE LIST REQUESTED FROM IMS HEALTH FOUNDATION FOR THE UNITED STATES 
IN 2014 
 
The NCGENES data utilized in this analysis included data from 672 individuals’ genomes.  This 
data analysis resulted in the identification of 223 individual genotypes that were potentially clinically 
actionable with exposure to relevant drugs.  180 people would require dose reduction, 40 people would 
20 
 
require an alternate drug, and 3 people would require serum monitoring.   The projected ANNS for this 
data set was 54.02.  The calculated mean ANNS for the simulated data is 54.11, with a 95% confidence 
interval from 53.94 to 54.30 using Monte Carlo simulation (based on 1000 simulated points).  See 
Appendix I for the complete listing of alleles, genotype, drug exposure, phenotype, action, and ARR. 
The following were the proportions of different actions based on the genotype and phenotype, for 
the NCGENES data set (Table 6). 
 
Possible Action Frequency 
Dose adjustment 80.7% 
Drug discontinuation or use of an alternative agent (i.e. 
clopidogrel) 
17.9% 
Monitoring of serum drug levels (i.e. voriconazole) 1.3% 
 
TABLE 6: PROPORTIONS OF DIFFERENT ACTIONS BASED ON THE GENOTYPE AND PHENOTYPE, FOR THE NCGENES DATA SET 
 
CUMC data utilized in this analysis included data from 2,983 individuals’ genomes.  This data 
analysis resulted in the identification of 1,483 genotypes that were potentially clinically actionable with 
exposure to relevant drugs.  The projected ANNS for this data set was 46.15.  Using Monte Carlo 
simulation, the calculated mean ANNS is 46.00 and the projected 95% confidence interval is from 45.93 
to 46.08.  See Appendix J for the complete listing of alleles, genotype, drug exposure, phenotype, action, 
and ARR. 
The following were the proportions of different actions based on the genotype and phenotype, for 
the CUMC data set (Table 7). 
Possible Action Frequency 
Dose adjustment 59.7% 
Drug discontinuation or use of an alternative agent (i.e. 
clopidogrel) 
27.9% 
Monitoring of serum drug levels (i.e. voriconazole) 12.4% 
TABLE 7: PROPORTIONS OF DIFFERENT ACTIONS BASED ON THE GENOTYPE AND PHENOTYPE, FOR THE CUMC DATA SET. 
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Importantly, CYP2D6 could not be adequately evaluated based on the variants called by the 
NCGENES and CUMC data sets.  This was due to both their complexity, and the unavailability of phase 
information, thus CYP2D6 variants were excluded from the analysis. 
General population data were used as a comparison, using the same guidelines and new 
prescription (NRX) data; this calculation was completed using genotype frequency data from PharmGKB 
and 1000 Genome project for the United States.  The calculated ANNS from the published data is 5.79 
people. The mean ANNS is 5.732 people with a projected 95% confidence interval of 5.72 to 5.76 based 
on Monte Carlo Simulation of variation in the data.  
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CHAPTER 5:  MODEL IMPLEMENTATION PLAN 
 
While the use of pharmacogenomic data in clinical practice is growing, the information is 
generally used in a retrospective manner.  The focus is on adverse drug events, and specific tests are 
generally done on individuals to help with clinical decision making.32  In the future, if pharmacogenomics 
can be proven to be cost effective and clinically useful, much more pharmacogenomic testing should be 
done preemptively, with a goal of having the data on hand for prevention of toxicity and for treatment 
optimization at the moment that a prescribing decision is entertained.  This would necessitate a change to 
either population-wide screening or screening of appropriately selected sub-populations as well as the 
use of large databases to store the information, and a mechanism for the provision of Pharmacogenomics 
results at point of care; thus shifting the focus to the selection of appropriate drug therapy based on 
knowledge of the patient’s pharmacogenomic phenotype.  
Several institutions that are part of the Translational Pharmacogenetic Program have published 
some of their early experiences with their efforts to implement such approaches into their respective 
healthcare systems; this model plan is heavily influenced by their experiences.  These institutions include 
Mayo Clinic, Ohio State University, St. Jude Children's Research Hospital, University of Florida, 
University of Maryland, and Vanderbilt University Medical Center University of Chicago and Brigham and 
Women's Hospital.  
While the current research has focused on the determination of the utility of reporting variants 
found in WES to guide patient management, ideally a model implementation plan would use these WES 
data more broadly.  A model implementation plan to use these data would not need to be coupled directly 
with its source, and indeed could be expected to be the same for many sources of pharmacogenomics 
data, including WES as we have explored, as well as pharmacogenomic panels done specifically to aid 
drug prescribing.  
23 
 
Once a means of obtaining these data consistently is available, the next step in integrating it into 
routine patient care will be laying the groundwork for implementation of preemptive reporting in the 
Electronic Health Record (EHR).  Such reports will need to include information about the abnormal 
genotype, and well as prescribing guidance.  Because “alert fatigue” is now a well-recognized 
consequence of EHRs, active interruptive alerts should probably be only be reserved for high significance 
results.  The knowledge needed to act on pharmacogenomic information is currently rapidly evolving, thus 
a way to provide information passively will also be desirable.  Thus, both passive information and active 
alerts are recommended as part of Computer Decision Support (CDS) in this model implementation plan. 
BARRIERS TO IMPLEMENTATION 
 
While the knowledge base and literature support for the use of pharmacogenomics to effect 
patient care is expanding, there still remain many barriers that the utilization of pharmacogenomics 
information to change prescribing practice (see Table 8).15,32,33 
 TABLE 8: BARRIERS TO IMPLEMENTATION 
 
First, pharmacogenomics information is not readily available in many settings.  Clinicians without 
access to both pharmacogenomics information and pharmacogenomics results can be expected continue 
to prescribe medications as they always have, due either to lack of knowledge of the risks for adverse 
events, or due to an inability to easily obtain pharmacogenomics information.  For example, codeine is 
still prescribed to patients whose CYP2D6 genotype is not known, despite strong evidence that patients 
who are CYP2D6 poor metabolizers are not likely to experience analgesia, and ultrarapid metabolizers 
are at increased risk of toxicity.  Studies of both physicians and pharmacists show that education about 
the utility of pharmacogenomics is inadequate.34-36  While the capability to conduct pre-prescribing genetic 
testing has been available for over ten years for some therapies, such testing has not become routine for 
Barriers to Implementation 
Lack of availability of results 
Lack of clinical education and guidance on how to use pharmacogenomics data in clinic 
Lack of acceptance of need for pharmacogenomics-directed prescribing 
Clinicians’ resistance to using genetic data in clinical practice 
Absence of infrastructure to handle genetic data 
Cost and reimbursement issues 
Time, workflow, and efficiency 
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most practitioners. In a survey of nearly 400,000 US physicians by Stanek et al in 2012, only 10.3% felt 
adequately informed about pharmacogenomic testing, only 12.9% had ordered testing within the prior 6 
months, and only 29.0% had received any education regarding pharmacogenomics. Despite relatively low 
response rates, the authors concluded that lack of effective physician education on the clinical value, 
availability, and interpretation of pharmacogenomic tests was a significant cause of poor uptake of 
pharmacogenomics in physician practices.33  Clinician education needs to include information about what 
tests are available, how to procure them, and how to interpret and apply the results to the patient’s 
care.34,37 
The lack of generalized acceptance of the need for pharmacogenomic testing to be incorporated 
into clinical decision making is multifactorial.  Issues include ingrained provider prescribing habits, and the 
timing of when computer decision support (CDS) alerts are provided.  Hayward showed that delivering 
suggestions for drug change at the moment of prescribing may be “too late” for the provider to change 
his/her decision-making process; rather, this information needs to be presented before the provider has 
decided what drug to use and started entering the order.38  Knowledge of how to use pharmacogenomic 
test results is also critical, and will require either improved provider education, or enhanced clinical 
decision support in the Electronic Health Record, or both.  As the pharmacogenomics knowledge 
continues to grow, a means of concomitantly updating the CDS system and developing provider 
knowledge should be considered. 
The current way providers treat patients most often takes place in the absence of patient-specific 
information about pharmacogenomics variants, with a lack of personal knowledge of how to use the 
results, and without education or CDS to help with prescribing decisions.  This decision flow is diagramed 
below (see figure 2). 
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FIGURE 2: THE CURRENT REACTIVE APPROACH TO DRUG PRESCRIBING, WHICH DOES NOT TAKE INTO ACCOUNT THE 
PHARMACOGENOMICS VARIANT STATUS. 
Pharmacogenomic testing 
results available 
yes no 
Normal 
genotype 
Patient encounter begins 
Drug ordered 
with confidence 
Abnormal 
pharmacogenotype 
Provider decides to use 
drug of 
pharmacogenomic 
significance 
Drug ordered 
Test 
results 
Alteration in 
prescribing 
Patient encounter ends 
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Cost is another barrier often cited to implementation of pharmacogenomics into care; 
reimbursement for genetic testing and interpretation hopefully will improve as the utility and cost savings 
in the prevention of adverse events becomes clearer, but so far there is little evidence that this is the 
case.  Of course one of the benefits of using WES data is that it is already available.  However, there is 
still a cost to reporting the additional results in terms of laboratorian time, the provision of passive 
interpretive information in the EHR, and the use of CDS with technical support for decision alerts.  This 
represents an additional barrier to implementation. 
 
ELEMENTS NEEDED FOR IMPLEMENTATION: 
 
Results of Whole Exome Sequencing will need to be made available for clinician use; in our data 
sets, these WES results were incidental findings for a different clinical question.  However, going forwards 
either WES results or Whole Genome Sequencing (WGS) results, or targeted and optimized 
pharmacogenomics panels can be used depending on the institution and the sub-population of interest.  
The clinical genotype will need to be reported, based on translating variants into genotypes, and their 
associated phenotypes.  Based on the analysis of benefits of reporting genotypes, decisions will need to 
be made about which genotypes and associated phenotypes to report.  Genotypic and phenotypic 
information, and its relevance to prescribing, will then need to be placed into the Electronic Health 
Record.   
In their article, Marsolo and Spooner identify five core EHR functions that are needed if genomic 
information is to be used in clinical care.39  These include: 
1. Storing genetic information as structured data; 
2. Standards based data to allow the information to move between different EHR systems; 
3. Rich phenotypic information which is stored as structured data and associated with relevant 
genetic information; 
4. Data made available for use by rules-based decision-support engines; and 
5. An EHR which can obtain and display information needed by the clinician to interpret the 
genotypic and phenotypic data. 
27 
 
 
Ideally, this information will be furnished to the provider prior to the decision about which drug to 
order.  In addition, if the provider enters a medication order, it would be desirable for the patient’s 
phenotype to be furnished, along with a recommendation regarding how to proceed based on the 
phenotype (and possible outcome).  This will involve decision support at the point of care, to guide the 
clinician in safe prescribing.  Clinician education regarding possible drug-gene or drug-drug interactions 
will also be necessary.   
There are several ways to provide information to facilitate use by the provider treating the patient.  
Information about the patient’s phenotype can be provided, along with guidance for use.  This can be in 
the form of a formal pharmacogenomics consultation note; in some settings this could take the form of an 
entry into the patient’s Problem List, or even information in the form of a letter, which in addition to being 
documented in the chart could be given to the patient, and made available to other relevant providers.  
Alerts can be programmed into the EHR that will provide information to the provider, either at the 
beginning of the patient encounter, or at the moment of drug prescribing.  As discussed above, giving the 
provider information prior to the decision about drug choice and discussion with the patient leads to more 
provider willingness to consider recommendations and to change the plan.38 
Consideration should be given to providing this sort of “passive interpretive” Clinical Decision 
Support (CDS) in the EHR, which could be viewed at the beginning of the patient encounter.  Clinical 
guidelines such as those by CPIC will need to be utilized to inform prescribing recommendations.  Other 
features in addition to the patient’s phenotype and its significance that should likely be included in CDS 
are: recommendations for dosing changes; need for monitoring; alternative drug recommendations; and 
patient education recommendations.  A combination of passive information and active alerts is expected 
to be the optimal way support the provider.  In the presence of pharmacogenomic information, the flow of 
the patient encounter and decision making regarding drug prescribing is diagrammed below in figure 3. 
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FIGURE 3: PROPOSED MODEL OF PHARMACOGENOMIC-BASED PRESCRIBING WITH ACTIVE\INTERRUPTIVE ALERTS. 
High risk phenotype 
yes no 
Active alert 
causes change 
in prescribing 
no yes 
Patient encounter begins 
Provider decides to use 
drug of 
pharmacogenomic 
significance 
Pharmacogenomic 
information available 
Drug ordered 
with confidence 
Patient encounter ends 
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Implementation of the reporting and subsequent use of pharmacogenomic variants of significance 
will take a multistep process, and require leadership and buy-in to optimize implementation.  The 
following necessary steps have been described to successfully implement preemptive 
Pharmacogenomics testing based on experience at St. Jude Children’s Hospital.15  First, there must be a 
standard way of getting testing result information into the EHR.  There must be a permissive institutional 
environment including both infrastructure and technical support.  There must also be an overseeing body 
which determines which test results are part of the EHR, and which drug-gene pairs are linked to active-
interruptive alerts.  There must be a process for keeping abreast of pharmacogenomic knowledge as the 
field advances, and this knowledge must be used in a standard process to update tests and clinical 
recommendations as the knowledge base expands.  
In addition to leadership support, implementation teams and stakeholders need to work 
collaboratively.  Such stakeholders will include clinical informatics and bioinformatics experts, providers 
(both specialists such as genetic counselors and geneticists, and generalists), pharmacists, information 
security and privacy personnel, and laboratorians. 
The process of developing the EHR interface and CDS content will need to involve users, 
decision makers, and evaluators. The users will need to be asked about the tasks they do on a daily basis 
to provide patient care, and about the clinical decisions that would benefit from computer decision 
support. 
Stakeholder/users should be surveyed to find out their needs, by asking questions in the following 
areas: 
1. What information do you need that you don’t have? 
2. Where in the EHR would pharmacogenomic information be located?  Would a link-out to a 
curated definitive information source help?  Or would you prefer a more concise summary linked 
to the moment of prescribing? Or both? 
3. How will you decide which drugs-gene pairs to implement alerts for in the EHR? 
4. What process will be used to update the system?  Who will be responsible?   
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5. How will new genomic results be put into the EHR, and converted to phenotypes with defined 
actions? 
6. Who will make sure that the pharmacogenomic actions are kept up to date with the rapidly 
advancing field? 
7. What do you want the CDS tool to look like?  What level of alerts do you want to see?  Do you 
want to be able to ignore an alert? 
8. Who will be responsible for monitoring the use of the alerts, and modifying ones which get 
ignored frequently? 
Once the needs of the providers and stakeholders have been identified, the CDS interface will be 
designed.  This will focus on the formatting and usability of the alerts and reminders, as it will likely be an 
add-on to an existing EHR platform with other types of alerts.   The targeted users will be shown the 
interface, and asked how to better integrate the pharmacogenomic knowledge base into the clinical work 
flow.   
There is a growing body of literature to inform the use of CDS.  As described by Kannry et al, the 
elements of a successful implementation and use of CDS include: 40   
1. active and actionable decision support,  
2. multiple rounds of usability testing with iterative development for user acceptance,  
3. numerous workflow events that result in CDS assistance,  
4. dedicated training and support for users of the CDS tool for user adoption, and 
5. support from clinical and administrative leadership.    
 
Frequent, unimportant alerts can distract clinicians, and limit the effectiveness of CDS.  One way 
to minimize this is to consider what information needs to be brought to the clinician’s attention as an 
“interruptive” alert, and what information can be presented more informatively.  Color and font can be 
used to portray the importance of the alert, and the level of user input needed to dismiss the alert can 
vary with the danger posed by overriding the alert.  The alert should include relevant patient data in the 
context of the alert and allowing clinicians to respond with one or two clicks. 41  Typing in response to the 
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alert should be kept at a minimum, especially if no one is reviewing the typed input.  It is important to put 
the information at the right point in the workflow, so that it is easily actionable. 
Horsky et al have made the following design recommendations for alerts and reminders for use in 
prescribing CDS 42:  
1. Tiered severity level: real-time, interruptive alerts should be reserved only for high severity 
warnings. 
2. Concise text with justification: content should be limited to 1-2 lines, with a brief justification 
separated visually. 
3. Clear response options: buttons with simple labels (order or cancel), with action links to possible 
alternate options. 
4. Concurrent alert priority: prioritize multiple alerts for a single order, with high-severity alerts 
emphasized. 
5. Unobtrusive reminders: for lower severity alerts, use flags or color-coded messages in reserved 
screen areas. 
6. Meaningful use of color: 5-6 colors at most to maintain emphasis, which correlate to risk across 
different scenarios.  Can use color shades for gradients. 
7. Text luminosity: high contrast ratio with dark text on light background; match color pairs if needed. 
8. Filtering rules: evaluate triggers to increase specificity and limit “false positives”. 
9. Curate and revise trigger rules: periodic reviews by a committee of frequently overridden alerts. 
10. Prompt for EHR edits: include a link to edit and update allergy and medication lists for alerts that 
are frequently overridden. 
 
A mock-up of the EHR and CDS interface should be designed based on these principles.  Two 
types of alerts should be used: one should be a warning, which gives strong advice to stop before 
ordering the drug, with a clearly specified reason (based on high risk phenotype being present).  The 
other should be more informative, with options for safe prescribing which may include further monitoring.  
Links directly to order sets should be provided so that the task of being cautious and following practice 
guidelines is made easy for the provider while reducing cognitive load.  The following are examples of 
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formatting for less and more serious alerts, with actions made simple by the use of order buttons 
integrated into the alerts. 
 
FIGURE 4: MOCK UP FOR CHANGE IN PRESCRIBING 
This patient is an intermediate metabolizer of mercaptopurine (based on genotype of TPMT); this may 
increase the risk of myelosuppression at usual doses.  
Guideline 
** Recommended action: use lower dose and watch for myelosuppression** 
 
mercaptopurine 0.75mg/kg daily 
 
CBC weekly 
 
 
mercaptopurine 1.5mg/kg daily  
Order 
Order 
Order despite risk of 
adverse event 
Warning: dose reduction and/or monitoring recommended 
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FIGURE 5: MOCK-UP FOR ACTIVE INTERRUPTIVE ALERT 
 
Once the interface for the Electronic Health Records has been designed, it should be tested on a 
small group of users.   A useful way of performing usability testing is to use the Post-Study System 
Usability Questionnaire (PSSUQ).  [See Appendix H.]  This is a 19 item scale that was initially developed 
for use at IBM to evaluate computer system usability; it has also been called the CSUQ (Computer 
System Usability Questionnaire).43  PSSUQ asks questions in five domains that are designed to assess 
the usability characteristics of the system: quick completion of work, ease of learning, high-quality 
documentation, functional task adequacy, and rapid acquisition of usability expertise for the system.  
Further studies of the psychometric features of the PSSUQ reveal that is comprised of a 3-factor structure 
(System Usefulness, Information Quality, and Interface Quality), and has significant generalizability over 
time and for different types of systems.44  
In addition to assessing the usability with the PSSUQ, evidence of ways the system is being 
utilized will be evaluated for needed changes.  Often PGx implementation into EHR will be based on 
either guidelines or protocols. In the case of guidelines, the level of adherence may need to be measured.   
This patient is a poor metabolizer of clopidogrel (based on high-risk genotype of CYP2C19); this may 
decrease the efficacy of the clopidogrel. 
Guideline 
** Recommended action: use alternative drug ** 
prasugrel 10mg p.o. daily  
or 
ticagrelor 90mg p.o. BID  
or 
Clopidogrel 75mg p.o. daily  
Warning: alternative drug recommended 
Order 
Order 
Order despite risk of 
lack of efficacy 
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Such guidelines may come from CPIC, or from a particular institutional committee or other organization. 
For protocols, the level of compliance may need to be measured. In regard to protocols, a specific clinical 
algorithm is implemented which then alters the path of care for the patient.  In this latter case integration 
into the EHR is critically important to keep track of both care quality and performance.  
The generation of alerts can be tracked, as can the use of provider overrides with medication 
prescribing.   If certain alerts are routinely ignored, these can be eliminated or changed to make sure they 
are relevant.  The use of the passive interpretive information can also be monitored, although the depth of 
understanding gained from this task or application to practice change will be less clear. Some examples 
of process measures are listed in table 8 and some examples of outcome measures are listed in table 9. 
Examples of Process Measures 
Was PGx data available in EHR? 
PGx  information in EHR reviewed prior to prescribing? 
How often was warning overridden? 
Recommended genotyping obtained prior to prescribing? 
TABLE 9: EXAMPLES OF PROCESS MEASURES 
 
Examples of Outcome Measures 
Number of drug related ADR in when warnings overridden 
Number of drug related ADRs when recommended testing not obtained 
Number of drug related ADRs when recommended alternate drugs or alternate dosing used 
TABLE 10: EXAMPLES OF OUTCOME MEASURES 
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CHAPTER 6: DISCUSSION 
 
This analysis has provided several results that require thoughtful interpretation to be meaningful, 
to help advance the understanding of pharmacogenomics, and to guide future research efforts.  There are 
also important implications for implementation within the healthcare system. The ANNS for both the 
CUMC data set and NCGENES data set were found to be fairly similar: 46 and 54 respectively.  However, 
they are an order of magnitude different from the approximation from the general population.    There are 
several possible explanations for these differences.  It is possible that the differences between the CUMC 
and NCGENES data sets are the due to a difference in the ethnic composition of the patients whose 
exomes are represented in the data sets; some genotypes and phenotypes are more common in certain 
races (i.e. G6PD deficiency in those of African origin); thus the location of the facility where the WES was 
done and the population in that catchment area may explain some of the difference in the ANNS results.   
However, it is unlikely that the population in either of these data sets was different enough from the 
general population to result in an order of magnitude in difference as compared to projections from 
available population data.  It is much more plausible that this difference is a consequence of the use of 
WES incidental findings to identify pharmacogenomically relevant variants with existing diagnostic WES 
bioinformatics pipelines rather than optimized methods for determining the presence of 
pharmacogenomics variants.   
Some of the limitations that were recognized during this work include the impracticality of 
determining the phase of multiple variants occurring within the same gene, a frequent occurrence in some 
common pharmacogenes.  For example, while there are many pharmacogenomic variants of significance 
in the CYP2D6 gene, the CYP2D6 data could not be used for either of these sets of experimental data 
because it was not possible to determine the phase of compound variants which are particularly relevant 
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in CYP2D6.  If the CYP2D6 data had been technically feasible to include (for example, by the use of a 
technique other than WES) the ANNS would have been even lower. 
In addition to the above limitations in the use of WES, other technical issues such as the use of 
primer sets, and bioinformatics pipelines that were not optimized to make accurate calls regarding these 
pharmacogenetic variants, makes the use of WES less than optimal and may have contributed further to 
the difference between our calculations based on the NCGENES and CUMC data and projections from 
population data. Certainly other approaches are well developed and exist, which can determine such 
variant alleles and other complex constructs, however, they are typically special purpose and do not 
provide for exploitation of incidental findings.  Another technology which is in its infancy which has some 
similarities with whole exome sequencing but which may permit the discrimination of phase in variant calls 
is whole genome sequencing. 
An initial goal was to determine if an aggregate number needed to screen per serious adverse 
event prevented could be computed.  Unfortunately, much of the literature and the PharmGKB knowledge 
base have focused on the question of evidence for an effect, not on the size or severity of the effect.  
Hence for many such adverse events the magnitude of the rate of the adverse reactions is not readily 
available in the literature. Therefore, the focus of the data analysis was on “actionable” variants rather 
than being stratified by severity.  Hence the number needed to screen to prevent an adverse event is 
expected to be much higher than the ANNS for clinical impact. 
It is also worth noting that, although there is utility in using WES for pharmacogenomics data if 
they are available, only a small (though growing) number of patients at most medical centers undergo 
such testing.   Thus WES is not expected to be a viable source of pharmacogenomic information for many 
patients presently.  However, in the future the number of WES results may increase, and in addition other 
technologies such as whole genome sequencing will probably become more prevalent and make 
implementation of pharmacogenomic results into patient care more feasible and likely to occur. 
Indeed it is most likely that an effort to implement reporting of pharmacogenomic findings from 
WES alone would not be compelling.  However, as genomic based analysis becomes more common, and 
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pharmacogenomics testing using a variety of methods and models become more common, all of these 
pharmacogenomically relevant data will need to be effectively integrated into patient care. 
The challenge of integrating knowledge into healthcare systems is well recognized in general. In 
the 2007 Workshop summarized in “The Learning Healthcare System” the IOM Roundtable on Evidence-
Based Medicine depicted their vision for a learning healthcare system in which “evidence is both applied 
and developed as a natural product of the care process.”45  However, they noted the need for expanded 
ability to produce such evidence to support medical care.  Nowhere is this likely to be truer than in 
implementing pharmacogenomics in such “learning healthcare systems.”  The model implementation plan 
proposed herein may form a backbone for creating such a system from a pharmacogenomics 
perspective. 
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CHAPTER 7: CONCLUSION 
 
There are a variety of lessons with general applicability that this analysis provides.  First, based 
on this analysis the pharmacogenomically relevant impact of WES based incidental screening is in the 
range of 46 to 52 persons needed to screen, even when using incidental findings from non-optimized 
WES.  When using a very sensitive test this number is expected to be very low, corresponding to an 
ANNS of 5.   This suggests that if such data were available that they could be quite useful in caring for 
patients.  It should be recalled, however, that this is the number needed to screen for a clinically relevant 
change in care, not the number to prevent an adverse event.  This latter number is expected to be much 
higher. 
Pharmacogenomics has the potential to impact the care of large numbers of patients currently 
receiving care within the US healthcare system.  Although WES has significant limitations when applied to 
pharmacogenomics, even when these are considered the expected aggregate number needed to screen 
is in the range of 46 to 52 for our data sets.  The use of whole genome sequencing in the future could 
make incidental pharmacogenomics findings more robust, and the aggregate number needed to screen 
may drop significantly.  However, it is worth noting that WES or WGS are unlikely to be performed on a 
large percentage of the patient population at any medical center for the foreseeable future.  
Pharmacogenomic information may be valuable enough that specific pre-emptive pharmacogenomics 
screening panels (likely to be array based) may be a much more common source of pharmacogenomic 
information. 
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APPENDIX A— LIST OF DRUGS WITH PHARMACOGENOMICS ON THE FDA 
LABEL 
 
Drug PHARMACOGE
NOMICS on 
FDA label 
FDA Label Excerpt 
Abacavir 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Genetic testing 
required 
All patients should be screened for the HLA-BCPIC A5701 allele 
prior to initiating therapy with ZIAGEN or reinitiation of therapy 
with ZIAGEN, unless patients have a previously documented 
HLA-BCPIC A5701 allele assessment.  
 
Patients who carry the HLA-BCPIC A5701 allele are at a higher 
risk of a hypersensitivity reaction to abacavir; although, 
hypersensitivity reactions have occurred in patients who do not 
carry the HLA-BCPIC A5701 allele.  ZIAGEN is contraindicated 
in patients: who have the HLA-BCPIC A5701 allele. 
Allopurinol 
CPIC A 
PharmGKB 1A 
none  
Amitriptyline 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
The biochemical activity of the drug metabolizing isozyme 
cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a 
subset of the Caucasian population (about 7% to 10% of 
Caucasians are so called "poor metabolizers")...Poor 
metabolizers have higher than expected plasma concentrations 
of tricyclic antidepressants (TCAs) when given usual doses...In 
addition, certain drugs inhibit the activity of this isozyme and 
make normal metabolizers resemble poor metabolizers...It is 
desirable to monitor TCA plasma levels whenever a TCA is 
going to be coadministered with another drug known to be an 
inhibitor of P450 2D6. 
aripiprazole 
CPIC B 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
Dosing recommendation in patients who are classified as 
CYP2D6 poor metabolizers (PM): The aripiprazole dose in PM 
patients should initially be reduced to one-half (50%) of the 
usual dose and then adjusted to achieve a favorable clinical 
response. The dose of aripiprazole for PM patients who are 
administered a strong CYP3A4 inhibitor should be reduced to 
one-quarter (25%) of the usual dose.  
 
Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, fluoxetine) 
inhibitors will increase ABILIFY drug concentrations; reduce 
ABILIFY dose to one-half of the usual dose when used 
concomitantly (2.6, 7.1), except when used as adjunctive 
treatment with antidepressants  
 
CYP3A4 inducers (eg, carbamazepine) will decrease ABILIFY 
drug concentrations; double ABILIFY dose when used 
concomitantly 
atomoxetine 
CPIC B 
Dutch guideline   
PharmGKB 2A 
Actionable 
Pharmacogeno
mics 
Atomoxetine is metabolized primarily through the CYP2D6 
enzymatic pathway. People with reduced activity in this pathway 
(PMs) have higher plasma concentrations of atomoxetine 
compared with people with normal activity (EMs). For PMs, AUC 
of atomoxetine is approximately 10-fold and Css,max is about 5-
fold greater than EMs. Laboratory tests are available to identify 
CYP2D6 PMs. Coadministration of STRATTERA with potent 
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inhibitors of CYP2D6, such as fluoxetine, paroxetine, or 
quinidine, results in a substantial increase in atomoxetine 
plasma exposure, and dosing adjustment may be necessary. 
 
A fraction of the population (about 7% of Caucasians and 2% of 
African Americans) are poor metabolizers (PMs) of CYP2D6 
metabolized drugs. These individuals have reduced activity in 
this pathway resulting in 10-fold higher AUCs, 5-fold higher 
peak plasma concentrations, and slower elimination (plasma 
half-life of about 24 hours) of atomoxetine compared with 
people with normal activity (extensive metabolizers (EMs)). 
Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and 
quinidine, cause similar increases in exposure. 
 
In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., 
paroxetine, fluoxetine, and quinidine) increase atomoxetine 
steady-state plasma concentrations to exposures similar to 
those observed in poor metabolizers (PMs). In EM individuals 
treated with paroxetine or fluoxetine, the AUC of atomoxetine is 
approximately 6- to 8-fold and Css,max is about 3- to 4-fold 
greater than atomoxetine alone. In vitro studies suggest that 
coadministration of cytochrome P450 inhibitors to PMs will not 
increase the plasma concentrations of atomoxetine. 
Azathioprine 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Genetic testing 
recommended 
Patients with intermediate thiopurine S-methyl transferase 
(TPMT) activity may be at an increased risk of myelotoxicity if 
receiving conventional doses of IMURAN. Patients with low or 
absent TPMT activity are at an increased risk of developing 
severe, life-threatening myelotoxicity if receiving conventional 
doses of IMURAN. TPMT genotyping or phenotyping can help 
identify patients who are at an increased risk for developing 
IMURAN toxicity 
 
TPMT Testing: It is recommended that consideration be given to 
either genotype or phenotype patients for TPMT. Phenotyping 
and genotyping methods are commercially available. The most 
common non-functional alleles associated with reduced levels of 
TPMT activity are TPMTCPIC A2, TPMTCPIC A3A and 
TPMTCPIC A3C. Patients with two nonfunctional alleles 
(homozygous) have low or absent TPMT activity and those with 
one non-functional allele (heterozygous) have intermediate 
activity. Accurate phenotyping (red blood cell TPMT activity) 
results are not possible in patients who have received recent 
blood transfusions. TPMT testing may also be considered in 
patients with abnormal CBC results that do not respond to dose 
reduction. Early drug discontinuation in these patients is 
advisable. TPMT TESTING CANNOT SUBSTITUTE FOR 
COMPLETE BLOOD COUNT (CBC) MONITORING IN 
PATIENTS RECEIVING IMURAN. See CLINICAL 
PHARMACOLOGY, WARNINGS, ADVERSE REACTIONS and 
DOSAGE AND ADMINISTRATION sections.  
 
One of the pathways for inactivation of azathioprine is inhibited 
by allopurinol. Patients receiving IMURAN and allopurinol 
concomitantly should have a dose reduction of IMURAN, to 
approximately 1/3 to 1/4 the usual dose. It is recommended that 
a further dose reduction or alternative therapies be considered 
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for patients with low or absent TPMT activity receiving IMURAN 
and allopurinol because both TPMT and XO inactivation 
pathways are affected. 
Capecitabin 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
Increased Risk of Severe or Fatal Adverse Reactions in Patients 
with Low or Absent Dihydropyrimidine Dehydrogenase (DPD) 
Activity: Withhold or permanently discontinue XELODA in 
patients with evidence of acute early-onset or unusually severe 
toxicity, which may indicate near complete or total absence of 
DPD activity. No XELODA dose has been proven safe in 
patients with absent DPD activity.  
Based on post-marketing reports, patients with certain 
homozygous or certain compound heterozygous mutations in 
the DPD gene that result in complete or near complete absence 
of DPD activity are at increased risk for acute early-onset of 
toxicity and severe, life-threatening, or fatal adverse reactions 
caused by XELODA (e.g., mucositis, diarrhea, neutropenia, and 
neurotoxicity). Patients with partial DPD activity may also have 
increased risk of severe, life-threatening, or fatal adverse 
reactions caused by XELODA.  
Carbamazepine 
CPIC A 
PharmGKB 1A 
Genetic testing 
required 
Retrospective case-control studies have found that in patients of 
Chinese ancestry there is a strong association between the risk 
of developing SJS/TEN with carbamazepine treatment and the 
presence of an inherited variant of the HLA-B gene, HLA-BCPIC 
A1502. The occurrence of higher rates of these reactions in 
countries with higher frequencies of this allele suggests that the 
risk may be increased in allele-positive individuals of any 
ethnicity. Across Asian populations, notable variation exists in 
the prevalence of HLA-BCPIC A1502. Greater than 15% of the 
population is reported positive in Hong Kong, Thailand, 
Malaysia, and parts of the Philippines, compared to about 10% 
in Taiwan and 4% in North China. South Asians, including 
Indians, appear to have intermediate prevalence of HLA-BCPIC 
A1502, averaging 2 to 4%, but higher in some groups. HLA-
BCPIC A1502 is present in <1% of the population in Japan and 
Korea. HLA-BCPIC A1502 is largely absent in individuals not of 
Asian origin (e.g., Caucasians, African-Americans, Hispanics, 
and Native Americans). 
 
Prior to initiating Tegretol therapy, testing for HLA-BCPIC A1502 
should be performed in patients with ancestry in populations in 
which HLA-BCPIC A1502 may be present. In deciding which 
patients to screen, the rates provided above for the prevalence 
of HLABCPIC A1502 may offer a rough guide, keeping in mind 
the limitations of these figures due to wide variability in rates 
even within ethnic groups, the difficulty in ascertaining ethnic 
ancestry, and the likelihood of mixed ancestry. Tegretol should 
not be used in patients positive for HLABCPIC A1502 unless the 
benefits clearly outweigh the risks. Tested patients who are 
found to be negative for the allele are thought to have a low risk 
of SJS/TEN. Over 90% of Tegretol treated patients who will 
experience SJS/TEN have this reaction within the first few 
months of treatment. This information may be taken into 
consideration in determining the need for screening of 
genetically at risk patients currently on Tegretol. 
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Celecoxib 
CPIC B 
PharmGKB 2A 
NO guideline 
Actionable 
Pharmacogeno
mics 
Poor Metabolizers of CYP2C9 Substrates: Patients who are 
known or suspected to be poor CYP2C9 metabolizers based on 
previous history/experience with other CYP2C9 substrates 
(such as warfarin, phenytoin) should be administered celecoxib 
with caution. Consider starting treatment at half the lowest 
recommended dose in poor metabolizers. Consider using 
alternative management in JRA patients who are poor 
metabolizers. 
 
Celecoxib metabolism is primarily mediated via CYP2C9. 
CYP2C9 activity is reduced in individuals with genetic 
polymorphisms that lead to reduced enzyme activity, such as 
those homozygous for the CYP2C9CPIC A2 and CYP2C9CPIC 
A3 polymorphisms. Limited data from 4 published reports that 
included a total of 8 subjects with the homozygous 
CYP2C9CPIC A3/CPIC A3 genotype showed celecoxib 
systemic levels that were 3- to 7-fold higher in these subjects 
compared to subjects with CYP2C9CPIC A1/CPIC A1 or CPIC 
AI/CPIC A3 genotypes. The pharmacokinetics of celecoxib have 
not been evaluated in subjects with other CYP2C9 
polymorphisms, such as CPIC A2, CPIC A5, CPIC A6, CPIC A9 
and CPIC A11. It is estimated that the frequency of the 
homozygous CPIC A3/CPIC A3 genotype is 0.3% to 1.0% in 
various ethnic groups. 
 
Consider a dose reduction by 50% (or alternative management 
for JRA) in patients who are known or suspected to be CYP2C9 
poor metabolizers. 
Chloroquine 
CPIC B 
PharmGKB 3 
NO guideline 
Actionable 
Pharmacogeno
mics 
Hematological Effects/Laboratory Tests  
Complete blood cell counts should be made periodically if 
patients are given prolonged therapy. If any severe blood 
disorder appears which is not attributable to the disease under 
treatment, discontinuance of the drug should be considered. 
The drug should be administered with caution to patients having 
G-6-PD (glucose-6 phosphate dehydrogenase) deficiency. 
Citalopram 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
In CYP2C19 poor metabolizers, citalopram steady state Cmax 
and AUC was increased by 68% and 107%, respectively. 
Celexa 20 mg/day is the maximum recommended dose in 
CYP2C19 poor metabolizers due to the risk of QT prolongation.  
 
In vitro studies suggest that citalopram is a relatively weak 
inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 
10 days) with the TCA imipramine (single dose of 100 mg), a 
substrate for CYP2D6, did not significantly affect the plasma 
concentrations of imipramine or citalopram. However, the 
concentration of the imipramine metabolite desipramine was 
increased by approximately 50%. The clinical significance of the 
desipramine change is unknown. Nevertheless, caution is 
indicated in the coadministration of TCAs with Celexa. 
Clobazam 
CPIC C 
PharmGKB 2A 
Actionable 
Pharmacogeno
mics 
Concentrations of clobazam's active metabolite, N-
desmethylclobazam, are higher in CYP2C19 poor metabolizers 
than in extensive metabolizers. For this reason, the initial dose 
in patients known to be CYP2C19 poor metabolizers should be 
5 mg/day. These patients should be titrated initially to 10-20 
mg/day, and may be titrated further to a maximum daily dose of 
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40 mg if tolerated...In CYP2C19 poor metabolizers, levels of N-
desmethylclobazam were 5-fold higher in plasma and 2- to 3-
fold higher in urine than in CYP2C19 extensive metabolizers. 
Clomipramine 
CPIC A and B 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
The biochemical activity of the drug metabolizing isozyme 
cytochrome P450 2D6...is reduced in a subset of the Caucasian 
population (about 7% to 10% of Caucasians are so-called "poor 
metabolizers"); reliable estimates of the prevalence of reduced 
P450 2D6 isozyme activity among Asian, African and other 
populations are not yet available. Poor metabolizers have higher 
than expected plasma concentrations of tricyclic 
antidepressants (TCAs) when given usual doses. Depending on 
the fraction of drug metabolized by P450 2D6, the increase in 
plasma concentration may be small, or quite large (8 fold 
increase in plasma AUC of the TCA). In addition, certain drugs 
inhibit the activity of this isozyme and make normal metabolizers 
resemble poor metabolizers...It is desirable to monitor TCA 
plasma levels whenever an agent of the tricyclic antidepressant 
class including Anafranil is going to be co-administered with 
another drug known to be an inhibitor of P450 2D6... 
Clopidogrel 
CPIC A 
PharmGKB 1A 
Dutch guideline   
 
Genetic testing 
recommended 
The effectiveness of Plavix is dependent on its activation to an 
active metabolite by the cytochrome P450 (CYP) system, 
principally CYP2C19...Plavix at recommended doses forms less 
of that metabolite and has a smaller effect on platelet function in 
patients who are CYP2C19 poor metabolizers. Poor 
metabolizers with acute coronary syndrome or undergoing 
percutaneous coronary intervention treated with Plavix at 
recommended doses exhibit higher cardiovascular event rates 
than do patients with normal CYP2C19 function. Tests are 
available to identify a patient's CYP2C19 genotype; these tests 
can be used as an aid in determining therapeutic strategy. 
Consider alternate treatment or treatment strategies in patients 
identified as CYP2C19 poor metabolizers. 
Clozapine 
CPIC C 
Actionable 
Pharmacogeno
mics 
Dose reduction may be necessary in patients who are CYP2D6 
poor metabolizers. Clozapine concentrations may be increased 
in these patients, because clozapine is almost completely 
metabolized and then excreted. A subset (3%–10%) of the 
population has reduced activity of CYP2D6 (CYP2D6 poor 
metabolizers). These individuals may develop higher than 
expected plasma concentrations of clozapine when given usual 
doses. 
 
Concomitant use of CLOZARIL with other drugs metabolized by 
CYP2D6 can increase levels of these CYPD26 substrates. Use 
caution when coadministering CLOZARIL with other drugs that 
are metabolized by CYP2D6. It may be necessary to use lower 
doses of such drugs than usually prescribed. Such drugs 
include specific antidepressants, phenothiazines, 
carbamazepine, and Type 1C antiarrhythmics (e.g., 
propafenone, flecainide, and encainide). 
Codeine 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
Some individuals may be ultra-rapid metabolizers due to a 
specific CYP2D6CPIC A2x2 genotype. These individuals 
convert codeine into its active metabolite, morphine, more 
rapidly and completely than other people. This rapid conversion 
results in higher than expected serum morphine levels. Even at 
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labeled dosage regimens, individuals who are ultra-rapid 
metabolizers may experience overdose symptoms such as 
extreme sleepiness, confusion, or shallow breathing. 
 
Codeine is secreted into human milk...some women are ultra-
rapid metabolizers of codeine. These women achieve higher-
than-expected serum levels of codeine's active metabolite, 
morphine, leading to higher-than-expected levels of morphine in 
breast milk and potentially dangerously high serum morphine 
levels in their breastfed infants. Therefore, maternal use of 
codeine can potentially lead to serious adverse reactions, 
including death, in nursing infants. 
Dabrafenib 
CPIC B/C 
Actionable 
PHARMACOGE
NOMICS 
TAFINLAR, which contains a sulfonamide moeity, confers a 
potential risk of hemolytic anemia in patients with glucose-6-
phosphate dehydrogenase (G6PD) deficiency. Closely observe 
patients with G6PD deficiency for signs of hemolytic anemia. 
Dapsone 
CPIC B 
PharmGKB 1b 
NO guideline 
Actionable 
Pharmacogeno
mics 
Oral dapsone treatment has produced dose-related hemolysis 
and hemolytic anemia. Individuals with glucose-6-phosphate 
dehydrogenase (G6PD) deficiency are more prone to hemolysis 
with the use of certain drugs...There was no evidence of 
clinically relevant hemolysis or anemia in patients treated with 
ACZONE Gel, 5%, including patients who were G6PD deficient. 
Some subjects with G6PD deficiency using ACZONE Gel 
developed laboratory changes suggestive of mild hemolysis. 
 
WARNINGS AND PRECAUTIONS 
Hematological Effects: Some subjects with G6PD deficiency 
using ACZONE Gel developed laboratory changes suggestive 
of mild hemolysis. (5.1)(8.6) 
Desipramine 
CPIC A 
PharmGKB 1A 
Actionable 
Pharmacogeno
mics 
 
The biochemical activity of the drug metabolizing isozyme 
cytochrome P450 2D6...is reduced in a subset of the Caucasian 
population (about 7% to 10% of Caucasians are so called "poor 
metabolizers"); reliable estimates of the prevalence of reduced 
P450 2D6 isozyme activity among Asian, African and other 
populations are not yet available. Poor metabolizers have higher 
than expected plasma concentrations of tricyclic 
antidepressants (TCAs) when given usual doses. Depending on 
the fraction of drug metabolized by P450 2D6, the increase in 
plasma concentration may be small, or quite large (8 fold 
increase in plasma AUC of the TCA). In addition, certain drugs 
inhibit the activity of this isozyme and make normal metabolizers 
resemble poor metabolizers...It is desirable to monitor TCA 
plasma levels whenever a TCA including is going to be co-
administered with another drug known to be an inhibitor of P450 
2D6. 
Dexlansoprazol
e 
CPIC B 
 
Actionable 
Pharmacogeno
mics 
In male Japanese subjects who received a single dose of 
DEXILANT 30 mg or 60 mg (N=2 to 6 subjects/group), mean 
dexlansoprazole Cmax and AUC values were up to 2 times 
higher in intermediate compared to extensive metabolizers; in 
poor metabolizers, mean Cmax was up to 4 times higher and 
mean AUC was up to 12 times higher compared to extensive 
metabolizers. Though such study was not conducted in 
Caucasians and African Americans, it is expected 
dexlansoprazole exposure in these races will be affected by 
CYP2C19 phenotypes as well. Concomitant administration of 
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dexlansoprazole and tacrolimus may increase whole blood 
levels of tacrolimus, especially in transplant patients who are 
intermediate or poor metabolizers of CYP2C19. 
Diazepam 
CPIC C 
PharmGKB 3 
Actionable 
Pharmacogeno
mics 
The metabolism of diazepam...involves demethylation (involving 
primarily CYP2C19 and CYP3A4) and 3-hydroxylation (involving 
primarily CYP3A4)...The marked inter-individual variability in 
clearance of diazepam reported in the literature is probably 
attributable to variability of CYP2C19...and CYP3A4. 
Doxepin 
CPIC A 
PharmGKB 
1A/3 Dutch 
guideline   
Actionable 
Pharmacogeno
mics 
 
Silenor is primarily metabolized by hepatic cytochrome P450 
isozymes CYP2C19 and CYP2D6, and to a lesser extent, by 
CYP1A2 and CYP2C9. Inhibitors of these isozymes may 
increase the exposure of doxepin. 
 
Since doxepin is metabolized by CYP2C19 and CYP2D6, 
inhibitors of these CYP isozymes may increase the exposure of 
doxepin. ...A maximum dose of doxepin in adults and elderly 
should be 3 mg, when doxepin is co-administered with 
cimetidine.  Poor metabolizers of CYP2C19 and CYP2D6 may 
have higher doxepin plasma levels than normal subjects. 
Escitalopram 
CPIC A 
PharmGKB 1A 
None   
esomeprazole 
CPIC B 
PharmGKB 3 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
CYP2C19 isoenzyme exhibits polymorphism in the metabolism 
of esomeprazole...At steady state, the ratio of AUC in Poor 
Metabolizers to AUC in the rest of the population (Extensive 
Metabolizers) is approximately 2. 
Fluorouracil 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
Excerpts from the Carac drug label: 
Carac should not be used in patients with dihydropyrimidine 
dehydrogenase (DPD) enzyme deficiency. A large percentage 
of fluorouracil is catabolized by the enzyme dihydropyrimidine 
dehydrogenase (DPD). DPD enzyme deficiency can result in 
shunting of fluorouracil to the anabolic pathway, leading to 
cytotoxic activity and potential toxicities. Patients should 
discontinue therapy with Carac if symptoms of DPD enzyme 
deficiency develop.  
 
Rarely, unexpected, systemic toxicity (e.g. stomatitis, diarrhea, 
neutropenia, and neurotoxicity) associated with parenteral 
administration of fluorouracil has been attributed to deficiency of 
dihydropyrimidine dehydrogenase 'DPD' activity. One case of 
life-threatening systemic toxicity has been reported with the 
topical use of 5% fluorouracil in a patient with a complete 
absence of DPD enzyme activity... Although this case was 
observed with 5% fluorouracil cream, it is unknown whether 
patients with profound DPD enzyme deficiency would develop 
systemic toxicity with lower concentrations of topically applied 
fluorouracil.  
 
Excerpts from the Adrucil drug label: 
Rarely, unexpected, severe toxicity (e.g., stomatitis, diarrhea, 
neutropenia and neurotoxicity) associated with 5-fluorouracil 
has been attributed to deficiency of dipyrimidine dehydrogenase 
activity. A few patients have been rechallenged with 5-
fluorouracil and despite 5-fluorouracil dose lowering, toxicity 
recurred and progressed with worse morbidity. Absence of this 
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catabolic enzyme appears to result in prolonged clearance of 5-
fluorouracil. 
Fluvoxamine 
CPIC A 
PharmGKB 1A 
Informative 
Pharmacogeno
mics 
 
Based on a finding of substantial interactions of fluvoxamine 
with certain of these drugs... and limited in vitro data for 
CYP3A4, it appears that fluvoxamine inhibits several 
cytochrome P450 isoenzymes that are known to be involved in 
the metabolism of others drugs such as: CYP1A2 (e.g., 
warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., 
warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 
(e.g.,omeprazole).  In vitro data suggest that fluvoxamine is a 
relatively weak inhibitor of CYP2D6. 
 
Caution is indicated in patients known to have reduced levels of 
cytochrome P450 2D6 activity and those receiving concomitant 
drugs known to inhibit this cytochrome P450 isoenzyme (e.g., 
quinidine). 
Glibenclamide 
CPIC B 
PharmGKB 3 
Actionable 
Pharmacogeno
mics 
Hemolytic Anemia: Treatment of patients with glucose 6-
phosphate dehydrogenase (G6PD) deficiency with sulfonylurea 
agents can lead to hemolytic anemia. Because GLYNASE 
PresTab belongs to the class of sulfonylurea agents, caution 
should be used in patients with G6PD deficiency and a non-
sulfonylurea alternative should be considered. 
Glimepiride 
CPIC B 
Actionable 
Pharmacogeno
mics 
Hemolytic Anemia: Sulfonylureas can cause hemolytic anemia 
in patients with glucose 6-phosphate dehydrogenase (G6PD) 
deficiency. Because AMARYL is a sulfonylurea, use caution in 
patients with G6PD deficiency and consider the use of a non-
sulfonylurea alternative. 
Glipizide 
CPIC B 
Actionable 
Pharmacogeno
mics 
Hemolytic Anemia: Treatment of patients with glucose-6-
phosphate dehydrogenase (G6PD) deficiency with sulfonylurea 
agents can lead to hemolytic anemia. Because GLUCOTROL 
belongs to the class of sulfonylurea agents, caution should be 
used in patients with G6PD deficiency and a non-sulfonylurea 
alternative should be considered. 
Iloperidone 
CPIC B/C 
PharmGKB 3 
Actionable 
Pharmacogeno
mics 
The observed mean elimination half-lives for iloperidone, P88 
and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 
and 23 hours, respectively, and in poor metabolizers (PM) are 
33, 37 and 31 hours, respectively. Steady-state concentrations 
are attained within 3-4 days of dosing. Iloperidone accumulation 
is predictable from single-dose pharmacokinetics. The 
pharmacokinetics of iloperidone is more than dose proportional. 
Elimination of iloperidone is mainly through hepatic metabolism 
involving two P450 isozymes, CYP2D6 and CYP3A4. 
 
Co-administration of FANAPT with known strong inhibitors of 
CYP2D6 like fluoxetine results in a 2.3 fold increase in 
iloperidone plasma exposure, and therefore one-half of the 
FANAPT dose should be administered. Similarly, PMs of 
CYP2D6 have higher exposure to iloperidone compared with 
EMs and PMs should have their dose reduced by one half. 
Laboratory tests are available to identify CYP2D6 PMs. 
FANAPT dose should be reduced by one-half when 
administered concomitantly with strong CYP3A4 inhibitors such 
as ketoconazole or clarithromycin. When the CYP3A4 inhibitor 
is withdrawn from the combination therapy, FANAPT dose 
should be increased to where it was before. 
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Imipramine 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
The biochemical activity of the drug metabolizing isozyme 
cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a 
subset of the Caucasian population (about 7% to 10% of 
Caucasians are so-called "poor metabolizers"); reliable 
estimates of the prevalence of reduced P450 2D6 isozyme 
activity among Asian, African, and other populations are not yet 
available. Poor metabolizers have higher than expected plasma 
concentrations of tricyclic antidepressants (TCAs) when given 
usual doses. Depending on the fraction of drug metabolized by 
P450 2D6, the increase in plasma concentration may be small, 
or quite large (8-fold increase in plasma AUC of the TCA). 
 
Concomitant use of tricyclic antidepressants with drugs that can 
inhibit cytochrome P450 2D6 may require lower doses than 
usually prescribed for either the tricyclic antidepressant or the 
other drug. 
irinotecan 
CPIC A 
PharmGKB 2A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
Individuals who are homozygous for the UGT1A1CPIC A28 
allele (UGT1A1 7/7 genotype) are at increased risk for 
neutropenia following initiation of CAMPTOSAR 
treatment...When administered in combination with other 
agents, or as a single-agent, a reduction in the starting dose by 
at least one level of CAMPTOSAR should be considered for 
patients known to be homozygous for the UGT1A1CPIC A28 
allele. 
Ivacaftor 
CPIC A 
PharmGKB 1A 
 
Genetic testing 
required 
 
KALYDECO is a cystic fibrosis transmembrane conductance 
regulator (CFTR) potentiator indicated for the treatment of cystic 
fibrosis (CF) in patients age 2 years and older who have one of 
the following mutations in the CFTR gene: G551D, G1244E, 
G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.  
KALYDECO is indicated for the treatment of CF in patients age 
2 years and older who have an R117H mutation in the CFTR 
gene. 
 
If the patient's genotype is unknown, an FDA-cleared CF 
mutation test should be used to detect the presence of a CFTR 
mutation followed by verification with bidirectional sequencing 
when recommended by the mutation test instructions for use. 
 
Limitations of Use: 
Not effective in patients with CF who are homozygous for the 
F508del mutation in the CFTR gene. 
Mafenide 
CPIC B 
Actionable 
Pharmacogeno
mics 
Fatal hemolytic anemia with disseminated intravascular 
coagulation, presumably related to a glucose-6-phosphate 
dehydrogenase deficiency, has been reported following therapy 
with SULFAMYLON Cream. 
Mercaptopurine 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Genetic testing 
recommended 
 
Mercaptopurine is inactivated via two major pathways. One is 
thiol methylation, which is catalyzed by the polymorphic enzyme 
thiopurine S-methyltransferase (TPMT), to form the inactive 
metabolite methyl-6-MP. TPMT activity is highly variable in 
patients because of a genetic polymorphism in the TPMT gene. 
For Caucasians and African Americans, approximately 0.3% 
(1:300) of patients have two non-functional alleles 
(homozygous-deficient) of the TPMT gene and have little or no 
detectable enzyme activity. Approximately 10% of patients have 
one TPMT non-functional allele (heterozygous) leading to low or 
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intermediate TPMT activity and 90% of individuals have normal 
TPMT activity with two functional alleles. Homozygous-deficient 
patients (two non-functional alleles), if given usual doses of 
mercaptopurine, accumulate excessive cellular concentrations 
of active thioguanine nucleotides predisposing them to 
PURINETHOL toxicity (see WARNINGS and PRECAUTIONS). 
Heterozygous patients with low or intermediate TPMT activity 
accumulate higher concentrations of active thioguanine 
nucleotides than people with normal TPMT activity and are 
more likely to experience mercaptopurine toxicity (see 
WARNINGS and PRECAUTIONS). TPMT genotyping or 
phenotyping (red blood cell TPMT activity) can identify patients 
who are homozygous deficient or have low or intermediate 
TPMT activity. 
 
If a patient has clinical or laboratory evidence of severe bone 
marrow toxicity, particularly myelosuppression, TPMT testing 
should be considered. 
methylene blue 
CPIC B 
PharmGKB 3 
Actionable 
Pharmacogeno
mics 
 
Methylene blue should be avoided in patients with G6PD 
deficiency due to the risk of paradoxical methemoglobinemia 
and hemolysis. 
Metoclopramid
e 
CPIC D 
Actionable 
Pharmacogeno
mics 
Patients with NADH-cytochrome b5 reductase deficiency are at 
an increased risk of developing methemoglobinemia and/or 
sulfhemoglobinemia when metoclopramide is administered. 
...neonates have reduced levels of NADH-cytochrome b5 
reductase which, in combination with the aforementioned 
pharmacokinetic factors, make neonates more susceptible to 
methemoglobinemia. 
Nalidixic acid 
CPIC B 
Actionable 
Pharmacogeno
mics 
Caution should be observed in patients with glucose-6-
phosphate dehydrogenase deficiency. ADVERSE 
REACTIONS...Other: Tendon disorders including tendon 
rupture, cholestasis, paresthesia, metabolic acidosis, 
thrombocytopenia, leukopenia, or hemolytic anemia, sometimes 
associated with glucose 6-phosphate dehydrogenase deficiency 
and peripheral neuropathy. 
Nilotinib 
CPIC C 
PharmGKB 3 
Genetic  
Testing required 
Tasigna can increase bilirubin levels. A pharmacogenetic 
analysis of 97 patients evaluated the polymorphisms of UGT1A1 
and its potential association with hyperbilirubinemia during 
Tasigna treatment. In this study, the (TA)7/(TA)7 genotype was 
associated with a statistically significant increase in the risk of 
hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 
genotypes. However, the largest increases in bilirubin were 
observed in the (TA)7/(TA)7 genotype (UGT1A1*28) patients. 
Nitrofurantoin 
CPIC B 
PharmGKB C 
NO guideline 
Actionable 
Pharmacogeno
mics 
 
Cases of hemolytic anemia of the primaquine-sensitivity type 
have been induced by nitrofurantoin. Hemolysis appears to be 
linked to a glucose-6-phosphate dehydrogenase deficiency in 
the red blood cells of the affected patients. This deficiency is 
found in 10 percent of Blacks and a small percentage of ethnic 
groups of Mediterranean and Near-Eastern origin. Hemolysis is 
an indication for discontinuing Furadantin; hemolysis ceases 
when the drug is withdrawn. 
Norfloxacin 
CPIC B 
NO guideline 
Actionable 
Pharmacogeno
mics 
Rarely, hemolytic reactions have been reported in patients with 
latent or actual defects in glucose-6-phosphate dehydrogenase 
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 activity who take quinolone antibacterial agents, including 
norfloxacin (see ADVERSE REACTIONS). 
 
Adverse Reactions...Hematologic: Neutropenia; leukopenia; 
agranulocytosis; hemolytic anemia, sometimes associated with 
glucose-6-phosphate dehydrogenase deficiency; 
thrombocytopenia. 
Nortriptyline 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
The biochemical activity of the drug metabolizing isozyme 
cytochrome P4502D6 (debrisoquin hydroxylase) is reduced in a 
subset of the Caucasian population (about 7% to 10% of 
Caucasians are so called 'poor metabolizers'); reliable estimates 
of the prevalence of reduced P4502D6 isozyme activity among 
Asian, African and other populations are not yet available. Poor 
metabolizers have higher than expected plasma concentrations 
of tricyclic antidepressants (TCAs) when given usual doses. 
Depending on the fraction of drug metabolized by P450 2D6, 
the increase in plasma concentration may be small, or quite 
large (8 fold increase in plasma AUC of the TCA). 
 
An individual who is stable on a given dose of TCA may become 
abruptly toxic when given one of these inhibiting drugs as 
concomitant therapy. The drugs that inhibit cytochrome P450 
2D6 include some that are not metabolized by the enzyme 
(quinidine; cimetidine) and many that are substrates for P450 
2D6 (many other antidepressants, phenothiazines, and the Type 
1C antiarrhythmics propafenone and flecainide). 
Oxycodone 
CPIC A 
PharmGKB 2A 
none  
Pantoprozole 
CPIC B 
PharmGKB 3 
Actionable 
Pharmacogeno
mics 
Pantoprazole is metabolized mainly by CYP2C19 and to minor 
extents by CYPs 3A4, 2D6, and 2C9. In in vivo drug-drug 
interaction studies with CYP2C19 substrates (diazepam (also a 
CYP3A4 substrate) and phenytoin (also a CYP3A4 inducer) and 
clopidogrel), nifedipine, midazolam, and clarithromycin 
(CYP3A4 substrates), metoprolol (a CYP2D6 substrate), 
diclofenac, naproxen and piroxicam (CYP2C9 substrates), and 
theophylline (a CYP1A2 substrate) in healthy subjects, the 
pharmacokinetics of pantoprazole were not significantly altered. 
 
For adult patients who are CYP2C19 poor metabolizers, no 
dosage adjustment is needed. Similar to adults, pediatric 
patients who have the poor metabolizer genotype of CYP2C19 
(CYP2C19 *2/*2) exhibited greater than a 6-fold increase in 
AUC compared to pediatric extensive (CYP2C19 *1/*1) and 
intermediate (CYP2C19 *1/*x) metabolizers. Poor metabolizers 
exhibited approximately 10-fold lower apparent oral clearance 
compared to extensive metabolizers. For known pediatric poor 
metabolizers, a dose reduction should be considered. 
Paroxetine 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Informative 
Pharmacogeno
mics 
 
The metabolism of paroxetine is accomplished in part by 
cytochrome CYP2D6. Saturation of this enzyme at clinical 
doses appears to account for the nonlinearity of paroxetine 
kinetics with increasing dose and increasing duration of 
treatment. The role of this enzyme in paroxetine metabolism 
also suggests potential drug-drug interactions.  In vitro drug 
interaction studies reveal that paroxetine inhibits CYP2D6. 
50 
 
Clinical drug interaction studies have been performed with 
substrates of CYP2D6 and show that paroxetine can inhibit the 
metabolism of drugs metabolized by CYP2D6 including 
desipramine, risperidone, and atomoxetine. 
 
Therefore, coadministration of paroxetine hydrochloride with 
other drugs that are metabolized by this isozyme, including 
certain drugs effective in the treatment of major depressive 
disorder (e.g., nortriptyline, amitriptyline, imipramine, 
desipramine, and fluoxetine), phenothiazines, risperidone, 
tamoxifen and Type 1C antiarrhythmics (e.g., propafenone, 
flecainide, and encainide), or that inhibit this enzyme (e.g., 
quinidine), should be approached with caution.  
 
However, due to the risk of serious ventricular arrhythmias and 
sudden death potentially associated with elevated plasma levels 
of thioridazine, paroxetine, and thioridazine should not be 
coadministered.  
Tamoxifen is a pro-drug requiring metabolic activation by 
CYP2D6. Inhibition of CYP2D6 by paroxetine may lead to 
reduced plasma concentrations of an active metabolite 
(endoxifen) and hence reduced efficacy of tamoxifen. 
Pazopanib 
CPIC B/C 
Actionable 
Pharmacogeno
mics 
Pazopanib can increase serum total bilirubin levels...In vitro 
studies showed that pazopanib inhibits UGT1A1, which 
glucuronidates bilirubin for elimination. In [a pooled 
pharmacogenetic] analysis, the (TA)7/(TA)7 genotype 
(UGT1A1*28/*28) (underlying genetic susceptibility to Gilbert's 
syndrome) was associated with a statistically significant 
increase in the incidence of hyperbilirubinemia relative to the 
(TA)6/(TA)6 and (TA)6/(TA)7 genotypes.  
 
If ALT elevations >3 X ULN occur concurrently with bilirubin 
elevations > 2 X ULN, VOTRIENT should be permanently 
discontinued. Patients should be monitored until resolution. 
VOTRIENT is a UGT1A1 inhibitor. Mild, indirect (uncojugated) 
hyperbilirubinemia may occur in patients with Gilbert's 
syndrome...Patients with only a mild indirect hyperbilirubinemia, 
known as Gilbert's syndrome, and elevation in ALT >3 X ULN 
should be managed as per the recommendations outlined for 
isolated ALT elevations. 
Peginterferon 
alfa-2a 
CPIC A 
PharmGKB 1A 
None  
peginterferon 
alfa-2b 
CPIC A 
PharmGKB 1A 
 
Actionable 
Pharmacogeno
mics 
 
When administering PegIntron with medications metabolized by 
CYP2C8/9 (e.g., warfarin and phenytoin) or CYP2D6 (e.g., 
flecainide), the therapeutic effect of these substrates may be 
decreased. 
 
A retrospective genome-wide association analysis1,2 of 1,671 
subjects (1,604 subjects from Study 4 and 67 subjects from 
another clinical trial) was performed to identify human genetic 
contributions to anti-HCV treatment response in previously 
untreated HCV genotype 1 subjects. A single nucleotide 
polymorphism near the gene encoding interferon-lambda-3 
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(IL28B rs12979860) was associated with variable SVR rates. 
The rs12979860 genotype was categorized as CC, CT and TT. 
In the pooled analysis of Caucasian, African-American, and 
Hispanic subjects from these trials (n=1,587), SVR rates by 
rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. 
TT 22%. The genotype frequencies differed depending on 
racial/ethnic background, but the relationship of SVR to IL28B 
genotype was consistent across various racial/ethnic groups 
(see Table 12). Other variants near the IL28B gene (e.g., 
rs8099917 and rs8103142) have been identified; however, they 
have not been shown to independently influence SVR rates 
during treatment with pegylated interferon alpha therapies 
combined with ribavirin 
Pegloticase 
CPIC B 
PharmGKB 3 
Genetic testing 
recommended 
Patients deficient in G6PD have reduced ability to reduce the 
hydrogen peroxide formed as a major byproduct of the 
pegloticase-catalyzed oxidation of uric acid to allantoin. Excerpt 
from the pegloticase (KRYSTEXXA) drug label: 
Before starting KRYSTEXXA, patients at higher risk for G6PD 
deficiency (e.g., those of African and Mediterranean ancestry) 
should be screened due to the risk of hemolysis and 
methemoglobinemia. 
Perphenazine 
CPIC B/C 
Actionable 
Pharmacogeno
mics 
The pharmacokinetics of perphenazine covary with the 
hydroxylation of debrisoquine which is mediated by cytochrome 
P4502D6 (CYP2D6) and thus is subject to genetic 
polymorphism, i.e., 7%-10% of Caucasians and a low 
percentage of Asians have little or no activity and are called 
"poor metabolizers". Poor metabolizers of CYP2D6 will 
metabolize perphenazine more slowly and will experience 
higher concentrations compared with normal or "extensive" 
metabolizers. Poor metabolizers demonstrate higher plasma 
concentrations of antipsychotic drugs at usual doses, which may 
correlate with emergence of side effects. Prospective 
phenotyping of elderly patients prior to antipsychotic treatment 
may identify those at risk for adverse events. 
 
The concomitant administration of other drugs that inhibit the 
activity of P4502D6 may acutely increase plasma 
concentrations of antipsychotics. Among these are tricyclic 
antidepressants and selective serotonin reuptake inhibitors, 
e.g., fluoxetine, sertraline and paroxetine. When prescribing 
these drugs to patients already receiving antipsychotic therapy, 
close monitoring is essential and dose reduction may become 
necessary to avoid toxicity. Lower doses than usually prescribed 
for either the antipsychotic or the other drug may be required. 
Phenytoin 
CPIC A 
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
There may be wide interpatient variability in phenytoin serum 
levels with equivalent dosages. Patients with unusually low 
levels may be noncompliant or hypermetabolizers of phenytoin. 
Unusually high levels result from liver disease, variant CYP2C9 
and CYP2C19 alleles, or drug interactions which result in 
metabolic interference. 
 
Phenytoin is metabolized by hepatic cytochrome P450 enzymes 
CYP2C9 and CYP2C19, and is particularly susceptible to 
inhibitory drug interactions because it is subject to saturable 
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metabolism. Inhibition of metabolism may produce significant 
increases in circulating phenytoin concentrations and enhance 
the risk of drug toxicity. Phenytoin is a potent inducer of hepatic 
drug-metabolizing enzymes. Serum level determinations for 
phenytoin are especially helpful when possible drug interactions 
are suspected. 
 
Studies in patients of Chinese ancestry have found a strong 
association between the risk of developing SJS/TEN and the 
presence of HLA-BCPIC A1502, an inherited allelic variant of 
the HLA B gene, in patients using carbamazepine. Limited 
evidence suggests that HLABCPIC A1502 may be a risk factor 
for the development of SJS/TEN in patients of Asian ancestry 
taking other antiepileptic drugs associated with SJS/TEN, 
including phenytoin. Consideration should be given to avoiding 
phenytoin as an alternative for carbamazepine in patients 
positive for HLA-BCPIC A1502. 
Pimozide 
CPIC B 
PharmGKB 4 
Genetic testing 
required 
Individuals with genetic variations resulting in poor CYP2D6 
metabolism (approximately 5 to 10% of the population) exhibit 
higher pimozide concentrations than extensive CYP2D6 
metabolizers. The concentrations observed in poor CYP 2D6 
metabolizers are similar to those seen with strong CYP2D6 
inhibitors such as paroxetine. The time to achieve steady state 
pimozide concentrations is expected to be longer 
(approximately 2 weeks) in poor CYP2D6 metabolizers because 
of the prolonged half-life. Alternative dosing strategies are 
recommended in patients who are genetically poor CYP2D6 
metabolizers. 
In children: At doses above 0.05mg/kg/day, CYP2D6 
genotyping should be performed. In poor CYP2D6 metabolizers, 
ORAP doses should not exceed 0.05mg/kg/day, and doses 
should not be increased earlier than 14 days. 
In adults: At doses above 4 mg/day, CYP2D6 genotyping should 
be performed. In poor CYP2D6 metabolizers, ORAP doses 
should not exceed 4 mg/day, and doses should not be 
increased earlier than 14 days. 
Primaquine 
CPIC B 
PharmGKB 3 
 
Actionable 
Pharmacogeno
mics 
If primaquine phosphate is prescribed for (1) an individual who 
has shown a previous idiosyncrasy to primaquine phosphate (as 
manifested by hemolytic anemia, methemoglobinemia, or 
leukopenia), (2) an individual with a family or personal history of 
favism, or (3) an individual with erythrocytic glucose-6-
phosphate dehydrogenase (G-6-PD) deficiency or nicotinamide 
adenine dinucleotide (NADH) methemoglobin reductase 
deficiency, the person should be observed closely for tolerance. 
The drug should be discontinued immediately if marked 
darkening of the urine or sudden decrease in hemoglobin 
concentration or leukocyte count occurs. 
Probenecid 
CPIC B 
  
Actionable 
Pharmacogeno
mics 
 
Hematologic: aplastic anemia, leukopenia, hemolytic anemia 
which in some patients could be related to genetic deficiency of 
glucose-6-phosphate dehydrogenase in red blood cells, anemia. 
Propafenone 
CPIC C 
PharmGKB 2A 
Actionable 
Pharmacogeno
mics 
 Propafenone is metabolized by CYP2D6,CYP3A4,and CYP1A2 
isoenzymes. Approximately 6% of Caucasians in the U.S. 
population are naturally deficient in CYP2D6 activity and to a 
somewhat lesser extent in other demographic groups. Drugs 
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that inhibit these CYP pathways(such as 
desipramine,paroxetine,ritonavir,sertraline for CYP2D6; 
ketoconazole, erythromycin, saquinavir, and grapefruit juice for 
CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can 
be expected to cause increased plasma levels of propafenone. 
Increased exposure to propafenone may lead to cardiac 
arrhythmias and exaggerated beta-adrenergic blocking activity. 
Because of its metabolism, the combination of CYP3A4 
inhibition and either CYP2D6 deficiency or CYP2D6 inhibition in 
users of propafenone is potentially hazardous. Therefore, avoid 
simultaneous use of propafenone ER capsules with both a 
CYP2D6 inhibitor and a CYP3A4 inhibitor. 
There are two genetically determined patterns of propafenone 
metabolism. In over 90% of patients, the drug is rapidly and 
extensively metabolized with an elimination half-life from 2-10 
hours. These patients metabolize propafenone into two active 
metabolites: 5-hydroxypropafenone which is formed by CYP2D6 
and N-depropylpropafenone (norpropafenone) which is formed 
by both CYP3A4 and CYP1A2. In less than 10% of patients, 
metabolism of propafenone is slower because the 5-hydroxy 
metabolite is not formed or is minimally formed. 
Protriptyline 
CPIC B  
Actionable 
Pharmacogeno
mics 
 
 The biochemical activity of the drug metabolizing isozyme 
cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in 
a subset of the Caucasian population (about 7% to 10% of 
Caucasians are so called "poor metabolizers"). Poor 
metabolizers have higher than expected plasma concentrations 
of tricyclic antidepressants (TCAs) when given usual doses. 
In addition, certain drugs inhibit the activity of this isozyme and 
make normal metabolizers resemble poor metabolizers. An 
individual who is stable on a given dose of TCA may become 
abruptly toxic when given one of these inhibiting drugs as 
concomitant therapy. The drugs that inhibit cytochrome P450 
2D6 include some that are not metabolized by the enzyme 
(quinidine; cimetidine) and many that are substrates for P450 
2D6 (many other antidepressants, phenothiazines, and the Type 
1C antiarrhythmics, propafenone and flecainide). 
Quinine 
CPIC B 
Actionable 
Pharmacogeno
mics 
QUALAQUIN is contraindicated in patients with the following: 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency. 
Hemolysis can occur in patients with G6PD deficiency receiving 
quinine.  
 
Desipramine (CYP2D6 susbtrate): Quinine (750 mg/day for 2 
days) decreased the metabolism of desipramine in patients who 
were extensive CYP2D6 metabolizers, but had no effect in 
patients who were poor CYP2D6 metabolizers. 
Rasburicase 
CPIC A 
PharmGKB 1A 
 
Genetic testing 
required 
 
Do not administer Elitek to patients with glucose-6-phosphate 
dehydrogenase (G6PD) deficiency. Immediately and 
permanently discontinue Elitek in patients developing 
hemolysis. Screen patients at higher risk for G6PD deficiency 
(e.g., patients of African or Mediterranean ancestry) prior to 
starting Elitek. 
 
Elitek is contraindicated in patients with G6PD deficiency 
because hydrogen peroxide is one of the major by-products of 
the conversion of uric acid to allantoin. In clinical studies, 
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hemolysis occurs in <1% patients receiving Elitek; severe 
hemolytic reactions occurred within 2-4 days of the start of 
Elitek. Immediately and permanently discontinue Elitek 
administration in any patient developing hemolysis. Institute 
appropriate patient monitoring and support measures (e.g., 
transfusion support). Screen patients at higher risk for G6PD 
deficiency (e.g., patients of African or Mediterranean ancestry) 
prior to starting Elitek. 
 
It is not known whether patients with deficiency of cytochrome 
b5 reductase (formerly known as methemoglobin reductase) or 
of other enzymes with antioxidant activity are at increased risk 
for methemoglobinemia or hemolytic anemia. 
Ribavirin 
CPIC A 
PharmGKB 1A 
None  
Sertraline 
CPIC B 
PharmGKB 1A 
None  
Simvastatin 
CPIC A 
PharmGKB 1A 
None  
Succinylcholin
e 
CPIC B 
PharmGKB 3 
Actionable 
Pharmacogeno
mics 
 
RISK OF CARDIAC ARREST FROM HYPERKALEMIC 
RHABDOMYOLYSIS 
There have been rare reports of acute rhabdomyolysis with 
hyperkalemia followed by ventricular dysrhythmias, cardiac 
arrest, and death after the administration of succinylcholine to 
apparently healthy children who were subsequently found to 
have undiagnosed skeletal muscle myopathy, most frequently 
Duchenne's muscular dystrophy. 
Succinylcholine is contraindicated in persons with personal or 
familial history of malignant hyperthermia, skeletal muscle 
myopathies, and known hypersensitivity to the drug. 
 
WARNINGS: SUCCINYLCHOLINE IS METABOLIZED BY 
PLASMA CHOLINESTERASE AND SHOULD BE USED WITH 
CAUTION, IF AT ALL, IN PATIENTS KNOWN TO BE OR 
SUSPECTED OF BEING HOMOZYGOUS FOR THE 
ATYPICAL PLASMA CHOLINESTERASE GENE. 
Patients homozygous for atypical plasma cholinesterase gene 
(1 in 2500 patients) are extremely sensitive to the 
neuromuscular blocking effect of succinylcholine. In these 
patients, a 5- to 10-mg test dose of succinylcholine may be 
administered to evaluate sensitivity to succinylcholine, or 
neuromuscular blockade may be produced by the cautious 
administration of a 1-mg/mL solution of succinylcholine by slow 
IV infusion. Apnea or prolonged muscle paralysis should be 
treated with controlled respiration. 
Sulfasalazine 
CPIC B 
PharmGKB 4 
Actionable 
Pharmacogeno
mics 
 
Patients with glucose-6 phosphate dehydrogenase deficiency 
should be observed closely for signs of hemolytic anemia. This 
reaction is frequently dose related. If toxic or hypersensitivity 
reactions occur, the drug should be discontinued immediately. 
Tacrolimus 
CPIC A 
PharmGKB 1A 
None  
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Tamoxifen 
CPIC A 
PharmGKB 2A 
None  
Tetrabenzine 
CPIC C 
Genetic testing 
requiring 
Patients requiring doses above 50 mg per day should be 
genotyped for the drug metabolizing enzyme CYP2D6 to 
determine if the patient is a poor metabolizer (PM) or an 
extensive metabolizer (EM). The maximum daily dose in PMs is 
50 mg with a maximum single dose of 25 mg. The maximum 
daily dose in EMs and intermediate metabolizers (IMs) 100 mg 
with a maximum single dose of 37.5 mg. 
 
Medications that are strong CYP2D6 inhibitors such as 
quinidine or antidepressants (e.g., fluoxetine, paroxetine) 
significantly increase the exposure to alpha-HTBZ and beta-
HTBZ, therefore, the total dose of XENAZINE should not 
exceed a maximum of 50 mg and the maximum single dose 
should not exceed 25 mg. 
Thioguanine 
CPIC A   
PharmGKB 1A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
There are individuals with an inherited deficiency of the enzyme 
thiopurine methyltransferase (TPMT) who may be unusually 
sensitive to the myelosuppressive effects of thioguanine and 
prone to developing rapid bone marrow suppression following 
the initiation of treatment. Substantial dosage reductions may be 
required to avoid the development of life-threatening bone 
marrow suppression in these patients. Prescribers should be 
aware that some laboratories offer testing for TPMT deficiency. 
Since bone marrow suppression may be associated with factors 
other than TPMT deficiency, TPMT testing may not identify all 
patients at risk for severe toxicity. Therefore, close monitoring of 
clinical and hematologic parameters is important. Bone marrow 
suppression could be exacerbated by coadministration with 
drugs that inhibit TPMT, such as olsalazine, mesalazine, or 
sulphasalazine. 
Thioridazine 
CPIC C 
PharmGKB 3 
 
Actionable 
Pharmacogeno
mics 
 
Thioridazine is used to treat schizophrenic patients. It has 
potentially fatal effects on heart rhythm and should only be used 
if other antipsychotic drugs are not effective or cause intolerable 
side effects. Its use is warned against in people with reduced 
CYP2D6 activity and hence, reduced clearance of the drug, as 
that increases the likelihood of the potential fatal effects. 
Therefore, thioridazine is contraindicated with these drugs as 
well as in patients, comprising about 7% of the normal 
population, who are known to have a genetic defect leading to 
reduced levels of activity of P450 2D6. 
Certain circumstances may increase the risk of Torsades de 
pointes and/or sudden death in association with the use of 
drugs that prolong the QTc interval, including 1) bradycardia, 2) 
hypokalemia, 3) concomitant use of other drugs that prolong the 
QTc interval, 4) presence of congenital prolongation of the QT 
interval, and 5) for thioridazine in particular, its use in patients 
with reduced activity of P450 2D6 or its coadministration with 
drugs that may inhibit P450 2D6 or by some other mechanism 
interfere with the clearance of thioridazine. 
tramadol 
CPIC A 
PharmGKB 1B 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
Approximately 7% of the population has reduced activity of the 
CYP2D6 isoenzyme of cytochrome P450. These individuals are 
"poor metabolizers" of debrisoquine, dextromethorphan, tricyclic 
antidepressants, among other drugs. Based on a population PK 
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analysis of Phase 1 studies in healthy subjects, concentrations 
of tramadol were approximately 20% higher in "poor 
metabolizers" versus "extensive metabolizers", while M1 
concentrations were 40% lower. In vitro drug interaction studies 
in human liver microsomes indicates that inhibitors of CYP2D6 
such as fluoxetine and its metabolite norfluoxetine, amitriptyline 
and quinidine inhibit the metabolism of tramadol to various 
degrees. The full pharmacological impact of these alterations in 
terms of either efficacy or safety is unknown. Concomitant use 
of SEROTONIN re-uptake INHIBITORS and MAO INHIBITORS 
may enhance the risk of adverse events, including seizure (see 
WARNINGS) and serotonin syndrome. 
Trimipramine 
CPIC A 
PharmGKB 1A 
 
 
Actionable 
Pharmacogeno
mics 
 
Poor metabolizers have higher than expected plasma 
concentrations of tricyclic antidepressants (TCAs) when given 
usual doses. Depending on the fraction of drug metabolized by 
P450 2D6, the increase in plasma concentration may be small, 
or quite large (8 fold increase in plasma AUC of the TCA). 
 
Concomitant use of tricyclic antidepressants with drugs that can 
inhibit cytochrome P450 2D6 may require lower doses than 
usually prescribed for either the tricyclic antidepressant or the 
other drug. 
voriconazole 
CPIC A 
PharmGKB 2A 
Dutch guideline   
Actionable 
Pharmacogeno
mics 
 
Inhibitors and inducers of CYP3A4, CYP2C9, and CYP2C19 
may alter VFEND concentrations. Adjust the VFEND dose and 
monitor for adverse events or lack of efficacy. 
 
VFEND may increase the concentrations and activity of drugs 
that are CYP3A4, CYP2C9 and CYP2C19 substrates. Reduce 
doses of and monitor for lack of efficacy or adverse events 
associated with drugs that are substrates of these enzymes. 
 
In vivo studies indicated that CYP2C19 is significantly involved 
in the metabolism of voriconazole. This enzyme exhibits genetic 
polymorphism. For example, 15-20% of Asian populations may 
be expected to be poor metabolizers. For Caucasians and 
Blacks, the prevalence of poor metabolizers is 35%. Studies 
conducted in Caucasian and Japanese healthy subjects have 
shown that poor metabolizers have, on average, 4-fold higher 
voriconazole exposure (AUCt) than their homozygous extensive 
metabolizer counterparts. Subjects who are heterozygous 
extensive metabolizers have, on average, 2-fold higher 
voriconazole exposure than their homozygous extensive 
metabolizer counterparts. 
Warfarin 
CPIC A 
PharmGKB 1A 
 
Actionable 
Pharmacogeno
mics 
 
The patient's CYP2C9 and VKORC1 genotype information, 
when available, can assist in selection of the starting dose. 
Table 5 describes the range of stable maintenance doses 
observed in multiple patients having different combinations of 
CYP2C9 and VKORC1 gene variants. Consider these ranges in 
choosing the initial dose. 
 
Known or suspected deficiency in protein C mediated 
anticoagulant response: Hereditary or acquired deficiencies of 
protein C or its cofactor, protein S, have been associated with 
tissue necrosis following warfarin administration. 
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APPENDIX B – DRUGS WITH CPIC GUIDELINE INFORMATION 
 
Drug Guidelines (from www.pharmgkb.org/guidelines) Updated 
bacavir CPIC  CPIC Guideline for abacavir and HLA-B  09/30/2014  
allopurinol CPIC  CPIC Guideline for allopurinol and HLA-B  06/12/2015  
amitriptyline CPIC  CPIC Guideline for amitriptyline and CYP2C19,CYP2D6  02/07/2014  
azathioprine CPIC  CPIC Guideline for azathioprine and TPMT  05/10/2016  
capecitabine CPIC  CPIC Guideline for capecitabine and DPYD  08/06/2014  
carbamazepine CPIC  CPIC Guideline for carbamazepine and HLA-B  02/07/2014  
citalopram CPIC  CPIC Guideline for citalopram,escitalopram and CYP2C19  05/11/2015  
clomipramine CPIC  CPIC Guideline for clomipramine and CYP2C19,CYP2D6  02/07/2014  
clopidogrel CPIC  CPIC Guideline for clopidogrel and CYP2C19  02/07/2014  
codeine CPIC  CPIC Guideline for codeine and CYP2D6  05/05/2016  
desipramine CPIC  CPIC Guideline for desipramine and CYP2D6  02/07/2014  
doxepin CPIC  CPIC Guideline for doxepin and CYP2C19,CYP2D6  02/07/2014  
escitalopram CPIC  CPIC Guideline for citalopram,escitalopram and CYP2C19  05/11/2015  
fluorouracil CPIC  CPIC Guideline for fluorouracil and DPYD  07/30/2014  
fluvoxamine CPIC  CPIC Guideline for fluvoxamine and CYP2D6  05/11/2015  
imipramine CPIC  CPIC Guideline for imipramine and CYP2C19,CYP2D6  02/07/2014  
ivacaftor CPIC  CPIC Guideline for ivacaftor and CFTR  05/16/2016  
mercaptopurine CPIC  CPIC Guideline for mercaptopurine and TPMT  05/10/2016  
nortriptyline CPIC  CPIC Guideline for nortriptyline and CYP2D6  02/07/2014  
paroxetine CPIC  CPIC Guideline for paroxetine and CYP2D6  05/11/2015  
peginterferon alfa-
2a 
CPIC  CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-
2b,ribavirin and IFNL3  
02/25/2016  
peginterferon alfa-
2b 
CPIC  CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-
2b,ribavirin and IFNL3  
02/25/2016  
phenytoin CPIC  CPIC Guideline for phenytoin and CYP2C9,HLA-B  02/03/2015  
rasburicase CPIC  CPIC Guideline for rasburicase and G6PD  05/09/2014  
ribavirin CPIC  CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-
2b,ribavirin and IFNL3  
02/25/2016  
sertraline CPIC  CPIC Guideline for sertraline and CYP2C19  05/11/2015  
simvastatin CPIC  CPIC Guideline for simvastatin and SLCO1B1  06/30/2014  
tacrolimus CPIC  CPIC Guideline for tacrolimus and CYP3A5  03/25/2015  
thioguanine CPIC  CPIC Guideline for thioguanine and TPMT  05/10/2016  
trimipramine CPIC  CPIC Guideline for trimipramine and CYP2C19,CYP2D6  02/07/2014  
warfarin CPIC  CPIC Guideline for warfarin and CYP2C9,VKORC1  06/19/2014  
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APPENDIX C – DRUG-GENE PAIRS, BASED ON THE LIST OF DRUGS IN 
APPENDIX A 
 
Drugs Genes 
abacavir HLA-B 
allopurinol HLA-B 
amitriptyline CYP2C19 
amitriptyline CYP2D6 
aripiprazole CYP2D6 
atomoxetine CYP2D6 
azathioprine TPMT 
boceprevir IFNL3 
capecitabine DPYD 
carbamazepine HLA-B 
celecoxib CYP2C9 
chloroquine G6PD 
citalopram CYP2C19 
clomipramine CYP2D6 
clopidogrel CYP2C19 
clozapine CYP2D6 
codeine CYP2D6 
dapsone G6PD 
desipramine CYP2D6 
doxepin CYP2C19 
doxepin CYP2D6 
escitalopram CYP2C19 
esomeprazole CYP2C19 
fluorouracil DPYD 
fluvoxamine CYP2D6 
imipramine CYP2C19 
imipramine CYP2D6 
irinotecan UGT1A1 
ivacaftor CFTR 
mercaptopurine TPMT 
methylene blue G6PD 
nitrofurantoin G6PD 
norfloxacin G6PD 
nortriptyline CYP2D6 
oxycodone CYP2D6 
paroxetine CYP2D6 
peginterferon alfa-2a IFNL3 
peginterferon alfa-2b IFNL3 
phenytoin CYP2C9 
phenytoin HLA-B 
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primaquine G6PD 
probenecid G6PD 
propafenone CYP2D6 
protriptyline CYP2D6 
rasburicase G6PD 
ribavirin IFNL3 
Selective serotonin 
reuptake inhibitors 
CYP2C19 
Selective serotonin 
reuptake inhibitors 
CYP2D6 
sertraline CYP2C19 
simvastatin SLCO1B1 
succinylcholine RYR1 
sulfasalazine G6PD 
tacrolimus CYP3A5 
tamoxifen CYP2D6 
telaprevir IFNL3 
tetrabenazine CYP2D6 
thioguanine TPMT 
thioridazine CYP2D6 
tramadol CYP2D6 
trimipramine CYP2C19 
trimipramine CYP2D6 
voriconazole CYP2C19 
warfarin CYP2C9 
warfarin VKORC1 
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APPENDIX D – TABLES OF ALLELIC VARIANTS AND PREDICTED GENE 
FUNCTION 
Allele Allele2 Phenotype Action Drug 
chance of drug 
exposure 
phenotype 
frequency US 
population 
CYP2C19*1 CYP2C19*17 UM do not use clomiprimine 0.000598587 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use escitalopram 0.040140272 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use citalopram 0.048015822 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use amitriptyline 0.019199168 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use imipramine 0.001382505 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use trimipramine 5.61573E-06 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use doxepin 0.00405065 0.0404634 
CYP2C19*1 CYP2C19*2 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*1 CYP2C19*3 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*1 CYP2C19*4 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*1 CYP2C19*5 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*1 CYP2C19*6 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*1 CYP2C19*7 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*1 CYP2C19*8 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*1 CYP2C19*17 UM do not use desipramine 0.000369207 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use protriptyline 6.21277E-05 0.0404634 
CYP2C19*1 CYP2C19*17 UM do not use nortriptyline 0.005517667 0.0404634 
CYP2C19*1 CYP2C19*2 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*1 CYP2C19*3 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*1 CYP2C19*4 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*1 CYP2C19*5 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*1 CYP2C19*6 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*1 CYP2C19*7 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*1 CYP2C19*8 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*1 CYP2C19*17 UM increase dose esomeprazole 0.01780649 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use clomiprimine 0.000598587 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use escitalopram 0.040140272 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use citalopram 0.048015822 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use amitriptyline 0.019199168 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use imipramine 0.001382505 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use trimipramine 5.61573E-06 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use doxepin 0.00405065 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use desipramine 0.000369207 0.0404634 
CYP2C19*17 CYP2C19*17 UM do not use protriptyline 6.21277E-05 0.0404634 
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CYP2C19*17 CYP2C19*17 UM do not use nortriptyline 0.005517667 0.0404634 
CYP2C19*17 CYP2C19*17 UM increase dose esomeprazole 0.01780649 0.0404634 
CYP2C19*2 CYP2C19*2 PM lower dose clomiprimine 0.000598587 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose clomiprimine 0.000598587 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose clomiprimine 0.000598587 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose clomiprimine 0.000598587 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose clomiprimine 0.000598587 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose clomiprimine 0.000598587 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose clomiprimine 0.000598587 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose escitalopram 0.040140272 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose escitalopram 0.040140272 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose escitalopram 0.040140272 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose escitalopram 0.040140272 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose escitalopram 0.040140272 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose escitalopram 0.040140272 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose escitalopram 0.040140272 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose citalopram 0.048015822 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose citalopram 0.048015822 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose citalopram 0.048015822 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose citalopram 0.048015822 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose citalopram 0.048015822 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose citalopram 0.048015822 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose citalopram 0.048015822 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose amitriptyline 0.019199168 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose amitriptyline 0.019199168 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose amitriptyline 0.019199168 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose amitriptyline 0.019199168 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose amitriptyline 0.019199168 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose amitriptyline 0.019199168 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose amitriptyline 0.019199168 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose imipramine 0.001382505 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose imipramine 0.001382505 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose imipramine 0.001382505 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose imipramine 0.001382505 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose imipramine 0.001382505 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose imipramine 0.001382505 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose imipramine 0.001382505 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose trimipramine 5.61573E-06 0.0330743 
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CYP2C19*2 CYP2C19*8 PM lower dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose doxepin 0.00405065 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose doxepin 0.00405065 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose doxepin 0.00405065 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose doxepin 0.00405065 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose doxepin 0.00405065 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose doxepin 0.00405065 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose doxepin 0.00405065 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose sertraline 0.059227331 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose sertraline 0.059227331 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose sertraline 0.059227331 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose sertraline 0.059227331 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose sertraline 0.059227331 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose sertraline 0.059227331 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose sertraline 0.059227331 0.0330743 
CYP2C19*2 CYP2C19*2 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*2 CYP2C19*3 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*2 CYP2C19*4 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*2 CYP2C19*5 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*2 CYP2C19*6 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*2 CYP2C19*7 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*2 CYP2C19*8 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*2 CYP2C19*17 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*2 CYP2C19*2 PM lower dose desipramine 0.000369207 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose desipramine 0.000369207 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose desipramine 0.000369207 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose desipramine 0.000369207 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose desipramine 0.000369207 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose desipramine 0.000369207 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose desipramine 0.000369207 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*2 CYP2C19*8 PM lower dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*2 CYP2C19*2 PM lower dose nortriptyline 0.005517667 0.0330743 
CYP2C19*2 CYP2C19*3 PM lower dose nortriptyline 0.005517667 0.0330743 
CYP2C19*2 CYP2C19*4 PM lower dose nortriptyline 0.005517667 0.0330743 
CYP2C19*2 CYP2C19*5 PM lower dose nortriptyline 0.005517667 0.0330743 
CYP2C19*2 CYP2C19*6 PM lower dose nortriptyline 0.005517667 0.0330743 
CYP2C19*2 CYP2C19*7 PM lower dose nortriptyline 0.005517667 0.0330743 
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CYP2C19*2 CYP2C19*8 PM lower dose nortriptyline 0.005517667 0.0330743 
CYP2C19*2 CYP2C19*2 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*2 CYP2C19*3 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*2 CYP2C19*4 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*2 CYP2C19*5 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*2 CYP2C19*6 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*2 CYP2C19*7 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*2 CYP2C19*8 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*2 CYP2C19*17 IM 
monitor serum 
level voriconazole 0.000118223 0.0702023 
CYP2C19*3 CYP2C19*3 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose trimipramine 5.61573E-06 0.0330743 
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CYP2C19*3 CYP2C19*4 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*3 CYP2C19*3 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*3 CYP2C19*4 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*3 CYP2C19*5 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*3 CYP2C19*6 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*3 CYP2C19*7 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*3 CYP2C19*8 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*3 CYP2C19*17 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*3 CYP2C19*3 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*3 CYP2C19*3 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*3 CYP2C19*4 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*3 CYP2C19*5 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*3 CYP2C19*6 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*3 CYP2C19*7 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*3 CYP2C19*8 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*3 CYP2C19*3 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
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CYP2C19*3 CYP2C19*4 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*3 CYP2C19*5 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*3 CYP2C19*6 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*3 CYP2C19*7 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*3 CYP2C19*8 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*3 CYP2C19*17 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*4 CYP2C19*4 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose doxepin 0.00405065 0.0330743 
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CYP2C19*4 CYP2C19*4 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*4 CYP2C19*4 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*4 CYP2C19*5 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*4 CYP2C19*6 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*4 CYP2C19*7 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*4 CYP2C19*8 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*4 CYP2C19*17 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*4 CYP2C19*4 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*4 CYP2C19*4 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*4 CYP2C19*5 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*4 CYP2C19*6 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*4 CYP2C19*7 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*4 CYP2C19*8 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*4 CYP2C19*4 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*4 CYP2C19*5 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*4 CYP2C19*6 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*4 CYP2C19*7 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*4 CYP2C19*8 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*4 CYP2C19*17 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*5 CYP2C19*5 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose citalopram 0.048015822 0.0330743 
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CYP2C19*5 CYP2C19*6 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*5 CYP2C19*5 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*5 CYP2C19*6 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*5 CYP2C19*7 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*5 CYP2C19*8 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*5 CYP2C19*17 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*5 CYP2C19*5 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*5 CYP2C19*5 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*5 CYP2C19*6 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*5 CYP2C19*7 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*5 CYP2C19*8 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*5 CYP2C19*5 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*5 CYP2C19*6 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
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CYP2C19*5 CYP2C19*7 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*5 CYP2C19*8 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*5 CYP2C19*17 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*6 CYP2C19*6 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*6 CYP2C19*6 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*6 CYP2C19*7 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*6 CYP2C19*8 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*6 CYP2C19*17 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*6 CYP2C19*6 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*6 CYP2C19*6 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*6 CYP2C19*7 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*6 CYP2C19*8 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*6 CYP2C19*6 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
69 
 
CYP2C19*6 CYP2C19*7 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*6 CYP2C19*8 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*6 CYP2C19*17 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*7 CYP2C19*7 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*7 CYP2C19*7 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*7 CYP2C19*8 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*7 CYP2C19*17 IM do not use clopidogrel 0.026818778 0.2755366 
CYP2C19*7 CYP2C19*7 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*7 CYP2C19*7 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*7 CYP2C19*8 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*7 CYP2C19*7 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*7 CYP2C19*8 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*7 CYP2C19*17 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
CYP2C19*8 CYP2C19*8 PM reduce dose clomiprimine 0.000598587 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose escitalopram 0.040140272 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose citalopram 0.048015822 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose amitriptyline 0.019199168 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose imipramine 0.001382505 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose trimipramine 5.61573E-06 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose doxepin 0.00405065 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose sertraline 0.059227331 0.0330743 
CYP2C19*8 CYP2C19*8 PM do not use clopidogrel 0.026818778 0.0330743 
CYP2C19*8 CYP2C19*17 IM do not use clopidogrel 0.026818778 0.2755366 
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CYP2C19*8 CYP2C19*8 PM reduce dose desipramine 0.000369207 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose protriptyline 6.21277E-05 0.0330743 
CYP2C19*8 CYP2C19*8 PM reduce dose nortriptyline 0.005517667 0.0330743 
CYP2C19*8 CYP2C19*8 PM 
moniter serum 
level voriconazole 0.000118223 0.0330743 
CYP2C19*8 CYP2C19*17 IM 
monitor serum 
level voriconazole 0.000118223 0.2755366 
     0 
CYP2C9*1 CYP2C9*2 IM reduce dose phenytoin 0.005406706 0.281289 
CYP2C9*1 CYP2C9*3 IM reduce dose phenytoin 0.005406706 0.281289 
CYP2C9*1 CYP2C9*2 IM reduce dose warfarin 0.051141392 0.281289 
CYP2C9*1 CYP2C9*3 IM reduce dose warfarin 0.051141392 0.281289 
CYP2C9*1 CYP2C9*2 IM reduce dose celecoxib 0.012455696 0.281289 
CYP2C9*1 CYP2C9*3 IM reduce dose celecoxib 0.012455696 0.281289 
CYP2C9*2 CYP2C9*2 PM reduce dose phenytoin 0.005406706 0.033258 
CYP2C9*2 CYP2C9*3 PM reduce dose phenytoin 0.005406706 0.033258 
CYP2C9*2 CYP2C9*2 PM reduce dose warfarin 0.051141392 0.033258 
CYP2C9*2 CYP2C9*3 PM reduce dose warfarin 0.051141392 0.033258 
CYP2C9*2 CYP2C9*2 PM reduce dose celecoxib 0.012455696 0.033258 
CYP2C9*2 CYP2C9*3 PM reduce dose celecoxib 0.012455696 0.033258 
CYP2C9*3 CYP2C9*3 PM reduce dose phenytoin 0.005406706 0.033258 
CYP2C9*3 CYP2C9*3 PM reduce dose warfarin 0.051141392 0.033258 
CYP2C9*3 CYP2C9*3 PM reduce dose celecoxib 0.012455696 0.033258 
      
CYP3A5*1 CYP3A5*2 IM change dose tacrolimus 0.002515466 0.058718273 
CYP3A5*1 CYP3A5*3 IM change dose tacrolimus 0.002515466 0.182786656 
CYP3A5*1 CYP3A5*6 IM change dose tacrolimus 0.002515466 0.017958538 
CYP3A5*1 CYP3A5*7 IM change dose tacrolimus 0.002515466 0.01925352 
      
DPYD 
rs67376798A 
DPYD 
rs67376798A PM use other drug capecitabine 0.000270053 0.000316526 
DPYD 
rs67376798A 
DPYD 
rs67376798A PM use other drug fluorouracil 0.002248282 0.000316526 
DPYD*1 DPYD*2A IM 
50% dose 
reduction capecitabine 0.000270053 0.013210141 
DPYD*1 DPYD*13 IM 
50% dose 
reduction capecitabine 0.000270053 0.001532499 
DPYD*1 
DPYD 
rs67376798A IM 
50% dose 
reduction capecitabine 0.000270053 0.032754607 
DPYD*1 DPYD*2A IM 
50% dose 
reduction fluorouracil 0.002248282 0.013210141 
DPYD*1 DPYD*13 IM 
50% dose 
reduction fluorouracil 0.002248282 0.001532499 
DPYD*1 
DPYD 
rs67376798A IM 
50% dose 
reduction fluorouracil 0.002248282 0.032754607 
DPYD*13 DPYD*13 PM use other drug capecitabine 0.000270053 7.701E-07 
DPYD*13 
DPYD 
rs67376798A PM use other drug capecitabine 0.000270053 0.000015402 
DPYD*13 DPYD*13 PM use other drug fluorouracil 0.002248282 7.701E-07 
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DPYD*13 
DPYD 
rs67376798A PM use other drug fluorouracil 0.002248282 0.000015402 
DPYD*2A DPYD*2A PM use other drug capecitabine 0.000270053 5.72218E-05 
DPYD*2A DPYD*13 PM use other drug capecitabine 0.000270053 1.32765E-05 
DPYD*2A 
DPYD 
rs67376798A PM use other drug capecitabine 0.000270053 0.00026553 
DPYD*2A DPYD*2A PM use other drug fluorouracil 0.002248282 5.72218E-05 
DPYD*2A DPYD*13 PM use other drug fluorouracil 0.002248282 1.32765E-05 
DPYD*2A 
DPYD 
rs67376798A PM use other drug fluorouracil 0.002248282 0.00026553 
      
G6PD I G6PD I 
severe 
deficiency use other drug rasburicase 1.86672E-08 0 
G6PD I G6PD I 
severe 
deficiency use other drug 
methylene 
blue 1.83561E-07 0 
G6PD II G6PD II 
10-60% of 
normal use other drug rasburicase 1.86672E-08 0.000003584 
G6PD II G6PD III 
10-60% of 
normal use other drug rasburicase 1.86672E-08 0 
G6PD II G6PD II 
10-60% of 
normal use other drug 
methylene 
blue 1.83561E-07 0.000003584 
G6PD II G6PD III 
10-60% of 
normal use other drug 
methylene 
blue 1.83561E-07 0 
G6PD III G6PD III 
10-60% of 
normal use other drug rasburicase 1.86672E-08 0.003698081 
G6PD III G6PD III 
10-60% of 
normal use other drug 
methylene 
blue 1.83561E-07 0.003698081 
      
HLA-B*15:02:01  use other drug phenytoin 0.005406706 0.2150754 
HLA-B*15:02:01  use other drug 
carbamaze
pine 0.005733557 0.2150754 
HLA-B*57:01:01  use other drug abacavir 0.000137142 0.1091776 
HLA-B*58:01:01  use other drug allopurinol 0.019266523 0.0284902 
      
IFNL-3: T IFNL-3; C  unfavorable ribavirin 0.000205209 0.39596586 
IFNL-3: T IFNL-3: T  unfavorable ribavirin 0.000205209 0.13415075 
IFNL-3: T IFNL-3; C  unfavorable bocepevir 9.42695E-07 0.39596586 
IFNL-3: T IFNL-3: T  unfavorable bocepevir 9.42695E-07 0.13415075 
IFNL-3: T IFNL-3; C  unfavorable telaprevir 7.80913E-07 0.39596586 
IFNL-3: T IFNL-3: T  unfavorable telaprevir 7.80913E-07 0.13415075 
      
SLCO1B1*1 SLCO1B1*5 IM 
lower dose or 
alt simvastatin 0.076296724 0.013153308 
SLCO1B1*1 SLCO1B1*15 IM 
lower dose or 
alt simvastatin 0.076296724 0.1993924 
SLCO1B1*1 SLCO1B1*17 IM 
lower dose or 
alt simvastatin 0.076296724 0.1993924 
SLCO1B1*15 SLCO1B1*15 PM 
lower dose or 
alt simvastatin 0.076296724 0.016736013 
SLCO1B1*15 SLCO1B1*17 PM 
lower dose or 
alt simvastatin 0.076296724 0.033472026 
SLCO1B1*17 SLCO1B1*17 PM 
lower dose or 
alt simvastatin 0.076296724 0.016736013 
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SLCO1B1*5 SLCO1B1*5 PM 
lower dose or 
alt simvastatin 0.076296724 0.002358526 
SLCO1B1*5 SLCO1B1*15 PM 
lower dose or 
alt simvastatin 0.076296724 0.003841151 
SLCO1B1*5 SLCO1B1*17 PM 
lower dose or 
alt simvastatin 0.076296724 0.003841151 
      
TPMT *3B TPMT *3B PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 1.63662E-07 
TPMT *3B TPMT *3C PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 2.98569E-06 
TPMT *3B TPMT*4 PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 4.26019E-06 
TPMT *3B TPMT *3B PM use other drug azathioprine 0.002105378 1.63662E-07 
TPMT *3B TPMT *3C PM use other drug azathioprine 0.002105378 2.98569E-06 
TPMT *3B TPMT*4 PM use other drug azathioprine 0.002105378 4.26019E-06 
TPMT *3B TPMT *3B PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 1.63662E-07 
TPMT *3B TPMT *3C PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 2.98569E-06 
TPMT *3B TPMT*4 PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 4.26019E-06 
TPMT *3C TPMT *3C PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 0.000704647 
TPMT *3C TPMT*4 PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 3.88592E-05 
TPMT *3C TPMT *3C PM use other drug azathioprine 0.002105378 0.000704647 
TPMT *3C TPMT*4 PM use other drug azathioprine 0.002105378 3.88592E-05 
TPMT *3C TPMT *3C PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 0.000704647 
TPMT *3C TPMT*4 PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 3.88592E-05 
TPMT*1 TPMT*2 IM lower dose thioguanine 5.84284E-06 0.003134738 
TPMT*1 TPMT*3A IM lower dose thioguanine 5.84284E-06 0.055365231 
TPMT*1 TPMT *3B IM lower dose thioguanine 5.84284E-06 0.000710032 
TPMT*1 TPMT *3C IM lower dose thioguanine 5.84284E-06 0.021257322 
TPMT*1 TPMT*4 IM lower dose thioguanine 5.84284E-06 0.0092412 
TPMT*1 TPMT*2 IM lower dose azathioprine 0.002105378 0.003134738 
TPMT*1 TPMT*3A IM lower dose azathioprine 0.002105378 0.055365231 
TPMT*1 TPMT *3B IM lower dose azathioprine 0.002105378 0.000710032 
TPMT*1 TPMT *3C IM lower dose azathioprine 0.002105378 0.021257322 
TPMT*1 TPMT*4 IM lower dose azathioprine 0.002105378 0.0092412 
TPMT*1 TPMT*2 IM lower dose 
mercaptopurin
e 0.000588765 0.003134738 
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TPMT*1 TPMT*3A IM lower dose 
mercaptopurin
e 0.000588765 0.055365231 
TPMT*1 TPMT *3B IM lower dose 
mercaptopurin
e 0.000588765 0.000710032 
TPMT*1 TPMT *3C IM lower dose 
mercaptopurin
e 0.000588765 0.021257322 
TPMT*1 TPMT*4 IM lower dose 
mercaptopurin
e 0.000588765 0.0092412 
TPMT*2 TPMT*2 PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 2.94641E-06 
TPMT*2 TPMT*3A PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 0.000104595 
TPMT*2 TPMT *3B PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 1.34906E-06 
TPMT*2 TPMT *3C PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 2.27023E-05 
TPMT*2 TPMT*4 PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 1.75583E-05 
TPMT*2 TPMT*2 PM use other drug azathioprine 0.002105378 2.86324E-06 
TPMT*2 TPMT*3A PM use other drug azathioprine 0.002105378 0.000104595 
TPMT*2 TPMT *3B PM use other drug azathioprine 0.002105378 1.34906E-06 
TPMT*2 TPMT *3C PM use other drug azathioprine 0.002105378 2.27023E-05 
TPMT*2 TPMT*4 PM use other drug azathioprine 0.002105378 1.75583E-05 
TPMT*2 TPMT*2 PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 2.86324E-06 
TPMT*2 TPMT*3A PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 0.000104595 
TPMT*2 TPMT *3B PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 1.34906E-06 
TPMT*2 TPMT *3C PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 2.27023E-05 
TPMT*2 TPMT*4 PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 1.75583E-05 
TPMT*3A TPMT*3A PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 0.000976515 
TPMT*3A TPMT *3B PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 2.52771E-05 
TPMT*3A TPMT *3C PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 0.000256765 
TPMT*3A TPMT*4 PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 0.000328987 
TPMT*3A TPMT*3A PM use other drug azathioprine 0.002105378 0.000976515 
TPMT*3A TPMT *3B PM use other drug azathioprine 0.002105378 2.52771E-05 
TPMT*3A TPMT *3C PM use other drug azathioprine 0.002105378 0.000256765 
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TPMT*3A TPMT*4 PM use other drug azathioprine 0.002105378 0.000328987 
TPMT*3A TPMT*3A PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 0.000976515 
TPMT*3A TPMT *3B PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 2.52771E-05 
TPMT*3A TPMT *3C PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 0.000256765 
TPMT*3A TPMT*4 PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 0.000328987 
TPMT*4 TPMT*4 PM 
use alt drug or 
90% dose 
reduce thioguanine 5.84284E-06 2.77236E-05 
TPMT*4 TPMT*4 PM use other drug azathioprine 0.002105378 2.77236E-05 
TPMT*4 TPMT*4 PM 
use alt drug or 
90% dose 
reduce 
mercaptopurin
e 0.000588765 2.77236E-05 
      
UGT1A1 *28 UGT1A1 *28 PM dose change irinotecan 2.25251E-06 0.09839775 
UGT1A1*1 UGT1A1 *28 IM dose change irinotecan 2.25251E-06 0.404637014 
UGT1A1*6 UGT1A1*6 PM dose change irinotecan 2.25251E-06 0.001251469 
UGT1A1*6 UGT1A1 *28 PM dose change irinotecan 2.25251E-06 0.007143267 
      
VKORC1 CT  change dose warfarin 0.051141392 0.422125311 
VKORC1 TT  change dose warfarin 0.051141392 0.188495045 
VKORC1  CC  change dose warfarin 0.051141392 0.348079645 
VKORC1 GG  change dose warfarin 0.051141392 0.348079645 
VKORC1 GA  change dose warfarin 0.051141392 0.422125311 
VKORC1 AA  change dose warfarin 0.051141392 0.188495045 
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APPENDIX E - SAS CODE FOR MONTE CARLO SENSITIVITY ANALYSIS OF 
ERROR 
 
 
*****   Calculating Aggragate Number Needed to Screen, with Monte Carlo 
Analysis Based 95% Confidence Interval for CUMC data  ****; 
 
/* 'DRPH.Action_Table' holds the observed values for 4 variables: Allele1, 
Allele2, Actionable and Drug.*/ 
/* Allele1 and Allele2 --are the allele names ( ie *1) */ 
/* Actionable-- is a binary variable determined by whether there is an 
actionable guideline for this genotype drug combination*/ 
/* Drug-- is the name of the drug in the guideline.*/ 
 
/* 'DRPH.Allele_Frequencies' holds the observed values for three variables 
Allele1, Allele2, and Population_frequency.*/ 
/* Allele1 and Allele2 --are the allele names ( ie *1) */ 
/* Population_Frequency-- is the reported allele frequency in an enthicity 
adjusted general population*/ 
 
/* Sort BY is used to merge 'DRPH.Action_Table' and 
'DRPH.CUMC_Genotype_Frequencies' in reference to 'Allele1' and 'Allele2' */ 
 
DATA Allele_Transition_Table1; 
 
set DRPH.Allele_Frequencies; 
 
Allele1=Gene; 
Allele2=Gene; 
population_frequency1=population_frequency; 
population_frequency2=population_frequency; 
 
RUN; 
 
DATA Allele_Transition_Table2; 
 
if 0 then set Allele_Transition_Table1 (keep= Allele1 population_frequency1);  
 declare hash hmerge(dataset: 'Allele_Transition_Table1'); 
  rc1 = hmerge.defineKey('Allele1'); 
  rc2 = hmerge.defineData('population_frequency1');  
  rc3 = hmerge.defineDone(); 
 do until(done); 
  set DRPH.Action_Table (keep= Allele1 Allele2 Actionable Drug) 
end=done;  
  rc4 = hmerge.find();  
  if rc4 = 0 then output Allele_Transition_Table2;  
 end;  
 stop;  
 
  
DATA Allele_Transition_Table3; 
 
if 0 then set Allele_Transition_Table1 (keep= Allele2 population_frequency2);  
 declare hash hmerge(dataset: 'Allele_Transition_Table1'); 
  rc1 = hmerge.defineKey('Allele2'); 
  rc2 = hmerge.defineData('population_frequency2');  
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  rc3 = hmerge.defineDone(); 
 do until(done); 
  set Allele_Transition_Table2 (keep= Allele1 Allele2 
population_frequency1 Actionable Drug) end=done;  
  rc4 = hmerge.find();  
  if rc4 = 0 then output Allele_Transition_Table3;  
 end;  
 stop;  
 
 
 /* convert drug names to all caps in 'Allele_Transition_Table' for hash 
object key matching and create a variable name that will match the key.*/ 
/* for the hash object defined below. */ 
 
DATA Cap_Allele_Transition_Table; 
 
Set Allele_Transition_Table3; 
 
 Combined_Molecule=UPCASE(Drug); 
 
RUN; 
/* the hash object 'hmerge' is created to add the frequency of observed NRx 
for each drug */ 
DATA Drug_Transition_Table; 
 
if 0 then set DRPH.odrugrisktotal (keep= Combined_Molecule 
NRx_MAT__Feb_2015);  
 declare hash hmerge(dataset:'DRPH.odrugrisktotal'); 
  rc1 = hmerge.defineKey('Combined_Molecule'); 
  rc2 = hmerge.defineData('NRx_MAT__Feb_2015');  
  rc3 = hmerge.defineDone(); 
 do until(done); 
  set Cap_Allele_Transition_Table  end=done; 
  rc4 = hmerge.find();  
  if rc4 = 0 then output Drug_Transition_Table;  
 end;  
 stop;  
 
 
/* both the absolute risk reduction weighted for genotype change and drug 
exposure chance is calculated for each genotype drug pair.*/ 
/* a standard error is calculated for both the genotype chance and drug 
exposure chance based on the large N approximation of the normal distribution 
to the */ 
/* binomial distribution if the number of observations are known.  If they 
are not known then the smallest noted number of observations from the 
literature is used.*/ 
/* In order to estimate the 95% confidence interval generate a random point 
measurement for the chance of drug exposure 'sDrugChance', the chance of 
having a specific genotype 'sGenotypeChance' */ 
/* related to knowing the genotype.  A normal distribution is used because, 
for large n it approaches the binomial distribution and can be calculated 
from frequency data and N. */ 
 
 
DATA Obs_Transition_Table; 
     SET Drug_Transition_Table; 
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    /* discard non-actionable entires in the table */ 
  IF actionable=1; 
  
/* to obtain the number needed to screen and an approximation of the 95% 
confidence interval the inverse of the */ 
/* aggregate absolute risk reduction both observed and simulated are 
calculated.*/ 
 
  oDrugChance= NRx_MAT__Feb_2015/321418820.0; /* total 2015 
population estimate from the US Census Bureau */ 
   
  /* the total number of observations is at least the number of new 
perscriptions */ 
  DrugChanceSD= SQRT(oDrugChance*(1.0-oDrugChance)); 
   
  
  If (Allele1 EQ Allele2) Then oGenoChance= 
population_frequency1**2; 
  Else oGenoChance=2.0*population_frequency1*population_frequency2; 
   
  oAllele1=population_frequency1; 
  oAllele2=population_frequency2; 
   
  oAllele1SD=SQRT(oAllele1*(1.0-oAllele1)); 
  oAllele2SD=SQRT(oAllele2*(1.0-oAllele2)); 
  oArr=oDrugChance*oGenoChance; 
 
 Run; 
 
DATA Sim_Transition_Table; 
     SET Obs_Transition_Table; 
  ARRAY sArr(1000) sArr1-sArr1000; 
  
/*For a point estimate, calculate the observed aggregate number needed to 
screen 'oANNS' based on the individual drug exposure chance means, */ 
/* genotype chance means based on observations. */ 
    
/* In order to estimate the 95% confidence interval generate a random point 
measurement for the chance of drug exposure 'sDrugChance', the chance of 
having a specific genotype 'sGenotypeChance' */ 
/* and the absolute risk reduction related to knowing the genotype. */ 
      DO I=1 to 1000; 
  /* Check to make sure standard deviation values are non-zero. If 
they are zero, use the mean value without variation since it would be very 
small.*/ 
  IF (DrugChanceSD NE 0.0) Then sDrugChance=RAND('Normal', 
oDrugChance, DrugChanceSD); 
  Else sDrugChance=oDrugChance; 
 
  IF (oAllele1SD NE 0.0) Then sAllele1=RAND('Normal', 
population_frequency1, oAllele1SD); 
  Else sAllele1=population_frequency1; 
 
  IF(oAllele2SD NE 0.0) Then sAllele2=RAND('Normal', 
population_frequency2, oAllele2SD); 
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  Else sAllele2=population_frequency2; 
 
  If (Allele1 EQ Allele2) Then sGenoChance= sAllele1**2; 
  Else sGenoChance=2.0*sAllele1*sAllele2; 
  sArr(I)=sDrugChance*sGenoChance; 
 
    END; 
RUN; 
    
 
DATA SUM_Transition_Table; 
set Sim_Transition_Table; 
 ARRAY sArr(1000) sArr1-sArr1000; 
 ARRAY SumArray (1000) SumArray1-SumArray1000; 
 
 RETAIN oAArr SumArray1-SumArray1000 0.0; 
 
   DO J=1 to 1000; 
  SumArray(J)+sArr(J); 
   END; 
 
 oAArr+oArr; 
 
 RUN; 
 
 DATA sResultsANNS; 
 ARRAY sArr(1000) sArr1-sArr1000; 
  ARRAY SumArray(1000) SumArray1-SumArray1000; 
 ARRAY sANNS(1000) sANNS1-sANNS1000; 
 SET SUM_Transition_Table; 
 
  DO J=1 to 1000; 
 sANNS(J)=1.0/MAX(SumArray(J)); 
  END; 
 
oANNS=1.0/MAX(oAArr); 
  
 RUN; 
 
DATA oANNS_Result; 
 
Set sResultsANNS(keep=oANNS ); 
 
Observed_Aggrigate_NNS= MAX(oANNS); 
 
     RUN; 
 
Proc Print Data=oANNS_Result; 
RUN; 
 
DATA sCL_Result; 
 
Set sResultsANNS(keep=sANNS1-sANNS1000); 
 
 
     RUN; 
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/* Use the simulated aggregate number needed to screen values 'sANNS' to 
calculate the 95% confidence interval for the observed aggregate number 
needed to screen */ 
/* 'oANNS'.*/ 
 
/* the data set is transposed so that the 1000 simulated ANNS values can be 
analysed as individual observations using Pro Means, */ 
 
  Proc Transpose DATA=sCL_Result OUT=sCL_Result_Transposed; 
 RUN; 
  
  PROC MEANS DATA=sCL_Result_Transposed N MEAN CLM RANGE; 
  VAR COL996; 
 
  RUN; 
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APPENDIX F - SAS PROGRAM FOR NCGENES DATA AND MONTE CARLO 
SIMULATION 
 
*****   Calculating Aggregate Number Needed to Screen, with Monte Carlo 
Analysis Based 95% Confidence Interval for CUMC data  ****; 
 
/* 'DRPH.Action_Table' holds the observed values for 4 variables: Allele1, 
Allele2, Actionable and Drug.*/ 
/* Allele1 and Allele2 --are the allele names ( ie *1) */ 
/* Actionable-- is a binary variable determined by whether there is an 
actionable guideline for this genotype drug combination*/ 
/* Drug-- is the name of the drug in the guideline.*/ 
 
/* 'DRPH.CUMC_Genotype_Frequencies' holds the observed values for three 
variables Allele1, Allele2, and frequency.*/ 
/* Allele1 and Allele2 --are the allele names ( ie *1) */ 
/* Frequency-- is the number of times the genotype was observed in the CUMC 
dataset*/ 
 
/* the hash object 'hmerge' is created to add the frequency of observed NRx 
for each drug */ 
 
DATA Obs_Transition_Table; 
     SET DRPH.ncgene_data; 
  
 
/* both the absolute risk reduction weighted for genotype change and drug 
exposure chance is calculated for each genotype drug pair.*/ 
/* a standard error is calculated for both the genotype chance and drug 
exposure chance based on the large N approximation of the normal distribution 
to the */ 
/* binomial distribution if the number of observations are known.  If they 
are not known then the smallest noted number of observations from the 
literature is used.*/ 
/* In order to estimate the 95% confidence interval generate a random point 
measurement for the chance of drug exposure 'sDrugChance', the chance of 
having a specific genotype 'sGenotypeChance' */ 
/* related to knowing the genotype.  A normal distribution is used because, 
for large n it approaches the binomial distribution and can be calculated 
from frequency data and N. */ 
 
 
  /* total 2015 population estimate from the US Census Bureau */ 
  oDrugChance=chance_of_drug_exposure; 
       
  oDrugChanceSD=SQRT(oDrugChance*(1.0-
oDrugChance)/number_of_drug_rx);   
 
/* standard error of the mean for large N approximation of normal 
distribution to binomial distribution. */ 
                                                                          
  oGenoChance= genotype_frequency;  
 
  oGenoChanceSD= SQRT(oGenoChance*(1.0-
oGenoChance)/number_of_cases); 
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  oArr=oDrugChance*oGenoChance; 
 
 Run; 
 
 /* Monte Carlo simulation of 1000 data points for each drug phenotype 
pair are created and the absolute reduction for each data point is 
calculated. */ 
   
DATA Sim_Transition_Table; 
     SET Obs_Transition_Table; 
  ARRAY sArr(1000) sArr1-sArr1000; 
  
      DO I=1 to 1000; 
   
  IF (DrugChanceSD NE 0.0) Then sDrugChance=ABS(RAND('Normal', 
oDrugChance, oDrugChanceSD)); 
  Else sDrugChance=oDrugChance; 
 
  IF (oGenoChanceSD NE 0.0) Then sGenoChance=ABS(RAND('Normal', 
oGenoChance, oGenoChanceSD)); 
  Else sGenoChance=oGenoChance; 
 
   
  sArr(I)=sDrugChance*sGenoChance; 
 
   END; 
 
 
RUN; 
    
/* Both the observed absolute risk reduction from the absolute risk reduction 
terms weighted for likelihood of drug exposure and */ 
/* the simulated absolute risk reduction terms weighted for likelihood of 
genotype and drug exposure are aggregated to form the observed */ 
/* aggregate absolute risk reduction and 1000 simulated aggregate absolute 
risk reduction point estimates respectively */ 
 
DATA SUM_Transition_Table; 
 Set Sim_Transition_Table; 
 ARRAY sArr(1000) sArr1-sArr1000; 
 ARRAY SumArray(1000) SumArray1-SumArray1000; 
 
 RETAIN oAArr SumArray1-SumArray1000 0.0; 
 
   DO J=1 to 1000; 
  SumArray(J)+sArr(J); 
   END; 
 
 oAArr+oArr; 
 
 RUN; 
/* to obtain the number needed to screen and an approximation of the 95% 
confidence interval the inverse of the */ 
/* aggregate absolute risk reduction both observed and simulated are 
calculated.*/ 
 
DATA sResultsANNS; 
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 ARRAY sArr(1000) sArr1-sArr1000; 
 ARRAY SumArray(1000) SumArray1-SumArray1000; 
 ARRAY sANNS(1000) sANNS1-sANNS1000; 
 SET SUM_Transition_Table; 
 
  DO J=1 to 1000; 
 sANNS(J)=1.0/MAX(SumArray(J)); 
  END; 
 
oANNS=1.0/MAX(oAArr); 
  
 RUN; 
 
DATA oANNS_Result; 
 
Set sResultsANNS(keep=oANNS ); 
 
Observed_Aggrigate_NNS= MAX(oANNS); 
 
     RUN; 
 
Proc Print Data=oANNS_Result; 
RUN; 
 
DATA sCL_Result; 
 
Set sResultsANNS(keep=sANNS1-sANNS1000); 
 
     RUN; 
 
/* Use the simulated aggregate number needed to screen values 'sANNS' to 
calculate the 95% confidence interval for the observed aggregate number 
needed to screen */ 
/* 'oANNS'.*/ 
 
/* the data set is transposed so that the 1000 simulated ANNS values can be 
analyzed as individual observations using Pro Means, */ 
 
  Proc Transpose DATA=sCL_Result OUT=sCL_Result_Transposed; 
 RUN; 
  
  PROC MEANS DATA=sCL_Result_Transposed N MEAN CLM RANGE; 
  VAR COL21; 
 
  RUN; 
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APPENDIX G - SAS PROGRAM FOR CUMC DATA AND MONTE CARLO 
SIMULATION 
 
*****   Calculating Aggregate Number Needed to Screen, with Monte Carlo 
Analysis Based 95% Confidence Interval for CUMC data  ****; 
 
/* 'DRPH.Action_Table' holds the observed values for 4 variables: Allele1, 
Allele2, Actionable and Drug.*/ 
/* Allele1 and Allele2 --are the allele names ( ie *1) */ 
/* Actionable-- is a binary variable determined by whether there is an 
actionable guideline for this genotype drug combination*/ 
/* Drug-- is the name of the drug in the guideline.*/ 
 
/* 'DRPH.CUMC_Genotype_Frequencies' holds the observed values for three 
variables Allele1, Allele2, and frequency.*/ 
/* Allele1 and Allele2 --are the allele names ( ie *1) */ 
/* Frequency-- is the number of times the genotype was observed in the CUMC 
dataset*/ 
 
DATA DRPH.CUMC_Genotypes_Concatonated; 
 
SET DRPH.CUMC_Genotype_Frequency; 
CONCATONATED_GENOTYPE=CAT(ALLELE1, ALLELE2); 
 
RUN; 
 
DATA DRPH.Action_Table_Concatonated; 
 
SET DRPH.Action_Table; 
CONCATONATED_GENOTYPE=CAT(ALLELE1, ALLELE2); 
 
RUN; 
 
DATA Allele_Transition_Table; 
 
if 0 then set DRPH.CUMC_Genotypes_Concatonated (keep= CONCATONATED_GENOTYPE 
COUNT);  
 declare hash hmerge(dataset: 'DRPH.CUMC_Genotypes_Concatonated'); 
  rc1 = hmerge.defineKey('CONCATONATED_GENOTYPE'); 
  rc2 = hmerge.defineData('COUNT');  
  rc3 = hmerge.defineDone(); 
 do until(done); 
  set DRPH.Action_Table_Concatonated (keep= Allele1 Allele2 
Actionable Drug CONCATONATED_GENOTYPE) end=done;  
  rc4 = hmerge.find();  
  if rc4 = 0 then output Allele_Transition_Table;  
 end;  
 stop;  
 
/* convert drug names to all caps in 'Allele_Transition_Table' for hash 
object key matching and create a variable name that will match the key.*/ 
/* for the hash object defined below. */ 
 
DATA Cap_Allele_Transition_Table; 
 
Set Allele_Transition_Table; 
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 Combined_Molecule=UPCASE(Drug); 
 
RUN; 
 
/* the hash object 'hmerge' is created to add the frequency of observed NRx 
for each drug */ 
 
DATA Drug_Transition_Table; 
 
if 0 then set DRPH.odrugrisktotal (keep= Combined_Molecule 
NRx_MAT__Feb_2015);  
 declare hash hmerge(dataset:'DRPH.odrugrisktotal'); 
  rc1 = hmerge.defineKey('Combined_Molecule'); 
  rc2 = hmerge.defineData('NRx_MAT__Feb_2015');  
  rc3 = hmerge.defineDone(); 
 do until(done); 
  set Cap_Allele_Transition_Table  end=done; 
  rc4 = hmerge.find();  
  if rc4 = 0 then output Drug_Transition_Table;  
 end;  
 stop;  
 
DATA Obs_Transition_Table; 
     SET Drug_Transition_Table; 
 
  /* discard non-actionable entries in the table */ 
   
  IF actionable=1; 
 
 
/* both the absolute risk reduction weighted for genotype change and drug 
exposure chance is calculated for each genotype drug pair.*/ 
/* a standard error is calculated for both the genotype chance and drug 
exposure chance based on the large N approximation of the normal distribution 
to the */ 
/* binomial distribution if the number of observations are known.  If they 
are not known then the smallest noted number of observations from the 
literature is used.*/ 
/* In order to estimate the 95% confidence interval generate a random point 
measurement for the chance of drug exposure 'sDrugChance', the chance of 
having a specific genotype 'sGenotypeChance' */ 
/* related to knowing the genotype.  A normal distribution is used because, 
for large n it approaches the binomial distribution and can be calculated 
from frequency data and N. */ 
 
  /* total 2015 population estimate from the US Census Bureau */ 
  oDrugChance= NRx_MAT__Feb_2015/321418820.0; 
       
  oDrugChanceSD=SQRT(oDrugChance*(1.0-
oDrugChance)/NRx_MAT__Feb_2015);   
 
/* standard error of the mean for large N approximation of normal 
distribution to binomial distribution.*/ 
                                                                          
  Ngeno=2983.0;  
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  oGenoChance= Count/Ngeno;   /* genotype frequency divided by the 
number of observations */ 
 
  oGenoChanceSD= SQRT(oGenoChance*(1.0-oGenoChance)/Ngeno); 
   
  oArr=oDrugChance*oGenoChance; 
 
 Run; 
 
 /* Monte Carlo simulation of 1000 data points for each drug phenotype 
pair are created and the absolute reduction for each data point is 
calculated. */ 
   
DATA Sim_Transition_Table; 
     SET Obs_Transition_Table; 
  ARRAY sArr(1000) sArr1-sArr1000; 
  
      DO I=1 to 1000; 
 
  IF (oDrugChanceSD NE 0.0) THEN sDrugChance=ABS(RAND('Normal', 
oDrugChance, oDrugChanceSD)); 
  ELSE sDrugChance= oDrugChance; 
 
  IF (oGenoChanceSD NE 0.0) THEN sGenoChance=ABS(RAND('Normal', 
oGenoChance, oGenoChanceSD)); 
  ELSE sGenoChance=oGenoChance; 
 
  sArr(I)=sDrugChance*sGenoChance; 
   END; 
 
RUN; 
    
/* Both the observed absolute risk reduction from the absolute risk reduction 
terms weighted for likelihood of drug exposure and */ 
/* the simulated absolute risk reduction terms weighted for likelihood of 
genotype and drug exposure are aggregated to form the observed */ 
/* aggregate absolute risk reduction and 1000 simulated aggregate absolute 
risk reduction point estimates respectively */ 
 
DATA SUM_Transition_Table; 
 Set Sim_Transition_Table; 
 ARRAY sArr(1000) sArr1-sArr1000; 
 ARRAY SumArray(1000) SumArray1-SumArray1000; 
 
 RETAIN oAArr SumArray1-SumArray1000 0.0; 
 
   DO J=1 to 1000; 
  SumArray(J)+sArr(J); 
   END; 
 
 oAArr+oArr; 
 
 RUN; 
/* to obtain the number needed to screen and an approximation of the 95% 
confidence interval the inverse of the */ 
/* aggregate absolute risk reduction both observed and simulated are 
calculated.*/ 
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DATA sResultsANNS; 
 ARRAY sArr(1000) sArr1-sArr1000; 
 ARRAY SumArray(1000) SumArray1-SumArray1000; 
 ARRAY sANNS(1000) sANNS1-sANNS1000; 
 SET SUM_Transition_Table; 
 
  DO J=1 to 1000; 
 sANNS(J)=1.0/MAX(SumArray(J)); 
  END; 
 
oANNS=1.0/MAX(oAArr); 
  
 RUN; 
 
DATA oANNS_Result; 
Set sResultsANNS(keep=oANNS ); 
Observed_Aggrigate_NNS= MAX(oANNS); 
 
    RUN; 
 
Proc Print Data=oANNS_Result; 
RUN; 
 
DATA sCL_Result; 
 
Set sResultsANNS(keep=sANNS1-sANNS1000); 
 
     RUN; 
 
/* Use the simulated aggregate number needed to screen values 'sANNS' to 
calculate the 95% confidence interval for the observed aggragate number 
needed to screen */ 
/* 'oANNS'.*/ 
 
/* the data set is transposed so that the 1000 simulated ANNS values can be 
analysed as individual observations using Pro Means, */ 
 
  Proc Transpose DATA=sCL_Result OUT=sCL_Result_Transposed; 
 RUN; 
 
  PROC MEANS DATA=sCL_Result_Transposed N MEAN CLM RANGE; 
  VAR COL23; 
 
  RUN; 
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APPENDIX H – POST-STUDY SYSTEM USABILITY QUESTIONNAIRE (PSSUQ)43 
 
Instructions and Items: 
This questionnaire gives you an opportunity to tell us your reactions to the system you used. Your 
responses will help us understand what aspects of the system you are particularly concerned about and 
the aspects that satisfy you.  To as great a degree as possible, think about all the tasks that you have 
done with the system while you answer these questions. 
Please read each statement and indicate how strongly you agree or disagree with the statement by 
circling a number on the scale.  (1 = strongly agree to 7 = strongly disagree) 
 
1. Overall, I am satisfied with how easy it is to use this system. 
2. It was simple to use this system. 
3. I could effectively complete the tasks and scenarios using this system. 
4. I was able to complete the tasks and scenarios quickly using this system. 
5. I was able to efficiently complete the tasks and scenarios using this system. 
6. I felt comfortable using this system. 
7. It was easy to learn to use this system. 
8. I believe I could become productive quickly using this system. 
9. The system gave error messages that clearly told me how to fix problems. 
10. Whenever I made a mistake using the system, I could recover easily and quickly. 
11. The information (such as on-line help, on-screen messages and other documentation) 
provided with this system was clear. 
12. It was easy to find the information I needed. 
13. The information provided for the system was easy to understand. 
14. The information was effective in helping me complete the tasks and scenarios. 
15. The organization of information on the system screens was clear. 
16. The interface of this system was pleasant. 
17. I liked using the interface of this system. 
18. This system has all the functions and capabilities I expect it to have. 
19. Overall, I am satisfied with this system. 
 
Rules for Calculating CSUQ/PSSUQ Scores 
You can calculate four scores from the responses to the PSSUQ items: 
* the overall satisfaction score (OVERALL), > Items 1 through 19 
* system usefulness (SYSUSE), > Items 1 through 8 
* information quality (INFOQUAL) > Items 9 through 15 and 
* interface quality (INTERQUAL). > Items 16 through 18 
 
 
 
 
 
  
88 
 
APPENDIX I – NCGENES RESULTS BY PHENOTYPE, DRUG, ACTION, AND ARR 
 
Allele 1 Allele 2 number 
of 
cases 
drug chance of 
drug 
exposure 
Pheno-
type 
action weighted ARR 
CYP2C19
*1 
CYP2C19*
4 
3 clopidogrel 0.026818778 IM do not use 0.000119727 
CYP2C19
*1 
CYP2C19*
4 
3 voriconazole 0.000118223 IM moniter 
serum 
level 
5.2778E-07 
HLA-
B*57:01:0
1  
 
37 abacavir 0.000137142 
 
use 
another 
drug 
7.55097E-06 
TPMT*1 TPMT*2 1 azathioprine 0.002105378 IM reduce 
dose 
3.133E-06 
TPMT*1 TPMT*2 1 mercaptopurin
e 
0.000588765 IM reduce 
dose 
8.76138E-07 
TPMT*1 TPMT*2 1 thioguanine 5.84284E-06 IM reduce 
dose 
8.69471E-09 
CYP2C9*
1 
CYP2C9*2 114 celecoxib 0.012455696 IM reduce 
dose 
0.00211302 
CYP2C9*
1 
CYP2C9*3 56 celecoxib 0.012455696 IM reduce 
dose 
0.001037975 
CYP2C9*
2 
CYP2C9*2 3 celecoxib 0.012455696 PM reduce 
dose 
5.56058E-05 
CYP2C9*
2 
CYP2C9*3 5 celecoxib 0.012455696 PM reduce 
dose 
9.26763E-05 
CYP2C9*
3 
CYP2C9*3 1 celecoxib 0.012455696 PM reduce 
dose 
1.85353E-05 
CYP2C9*
1 
CYP2C9*2 114 phenytoin 0.005406706 IM reduce 
dose 
0.000917209 
CYP2C9*
1 
CYP2C9*3 56 phenytoin 0.005406706 IM reduce 
dose 
0.000450559 
CYP2C9*
2 
CYP2C9*2 3 phenytoin 0.005406706 PM reduce 
dose 
2.41371E-05 
CYP2C9*
2 
CYP2C9*3 5 phenytoin 0.005406706 PM reduce 
dose 
4.02285E-05 
CYP2C9*
3 
CYP2C9*3 1 phenytoin 0.005406706 PM reduce 
dose 
8.04569E-06 
CYP2C9*
1 
CYP2C9*2 114 warfarin 0.051141392 IM reduce 
dose 
0.008675772 
CYP2C9*
1 
CYP2C9*3 56 warfarin 0.051141392 IM reduce 
dose 
0.004261783 
CYP2C9*
2 
CYP2C9*2 3 warfarin 0.051141392 PM reduce 
dose 
0.00022831 
CYP2C9*
2 
CYP2C9*3 5 warfarin 0.051141392 PM reduce 
dose 
0.000380516 
CYP2C9*
3 
CYP2C9*3 1 warfarin 0.051141392 PM reduce 
dose 
7.61033E-05 
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APPENDIX J – CUMC RESULTS BY PHENOTYPE, DRUG, ACTION, AND ARR 
 
 
Allele1 Allele2 
Genotype 
frequency 
Number 
of Cases Drug 
Chance 
of drug 
exposure 
Pheno-
type Action 
Weighted 
ARR    
CYP2C19*
2 CYP2C19*1 0.1240 370 clopidogrel 0.0268 IM do not use 0.003324170    
CYP2C19*
2 CYP2C19*1 0.1240 370 voriconazole 0.0001 IM 
monitor 
serum level 0.000012404    
CYP2C19*
2 CYP2C19*1 0.1240 370 phenytoin 0.0054 IM reduce dose 0.000669796    
CYP2C19*
4 CYP2C19*2 0.0007 2 clopidogrel 0.0268 PM do not use 0.000017968    
CYP2C19*
4 CYP2C19*2 0.0007 2 voriconazole 0.0001 PM 
moniter 
serum level 0.000000067    
CYP2C19*
4 CYP2C19*2 0.0007 2 nortriptyline 0.0055 PM lower dose 0.000003688    
CYP2C19*
4 CYP2C19*2 0.0007 2 protriptyline 0.0001 PM lower dose 0.000000067    
CYP2C19*
4 CYP2C19*2 0.0007 2 desipramine 0.0004 PM lower dose 0.000000268    
CYP2C19*
4 CYP2C19*2 0.0007 2 sertraline 0.0592 PM lower dose 0.000039692    
CYP2C19*
4 CYP2C19*2 0.0007 2 doxepin 0.0041 PM lower dose 0.000002749    
CYP2C19*
4 CYP2C19*2 0.0007 2 trimipramine 0.0000 PM lower dose 0.000000003    
CYP2C19*
4 CYP2C19*2 0.0007 2 imipramine 0.0014 PM lower dose 0.000000939    
CYP2C19*
4 CYP2C19*2 0.0007 2 amitriptyline 0.0192 PM lower dose 0.000012873    
CYP2C19*
4 CYP2C19*2 0.0007 2 citalopram 0.0480 PM lower dose 0.000032182    
CYP2C19*
4 CYP2C19*2 0.0007 2 escitalopram 0.0401 PM lower dose 0.000026886    
CYP2C19*
4 CYP2C19*2 0.0007 2 clomiprimine 0.0006 PM lower dose 0.000000402    
CYP2C19*
4 CYP2C19*1 0.0030 9 clopidogrel 0.0268 IM do not use 0.000080858    
CYP2C19*
4 CYP2C19*1 0.0030 9 voriconazole 0.0001 IM 
monitor 
serum level 0.000000302    
CYP2C19*
4 CYP2C19*1 0.0030 9 phenytoin 0.0054 IM reduce dose 0.000016292    
CYP2C19*
8 CYP2C19*2 0.0007 2 clopidogrel 0.0268 PM do not use 0.000017968    
CYP2C19*
8 CYP2C19*2 0.0007 2 voriconazole 0.0001 PM 
moniter 
serum level 0.000000067    
CYP2C19*
8 CYP2C19*2 0.0007 2 nortriptyline 0.0055 PM lower dose 0.000003688    
CYP2C19*
8 CYP2C19*2 0.0007 2 protriptyline 0.0001 PM lower dose 0.000000067    
CYP2C19*
8 CYP2C19*2 0.0007 2 desipramine 0.0004 PM lower dose 0.000000268    
CYP2C19*
8 CYP2C19*2 0.0007 2 sertraline 0.0592 PM lower dose 0.000039692    
CYP2C19*
8 CYP2C19*2 0.0007 2 doxepin 0.0041 PM lower dose 0.000002749    
CYP2C19*
8 CYP2C19*2 0.0007 2 trimipramine 0.0000 PM lower dose 0.000000003    
CYP2C19*
8 CYP2C19*2 0.0007 2 imipramine 0.0014 PM lower dose 0.000000939    
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CYP2C19*
8 CYP2C19*2 0.0007 2 amitriptyline 0.0192 PM lower dose 0.000012873    
CYP2C19*
8 CYP2C19*2 0.0007 2 citalopram 0.0480 PM lower dose 0.000032182    
CYP2C19*
8 CYP2C19*2 0.0007 2 escitalopram 0.0401 PM lower dose 0.000026886    
CYP2C19*
8 CYP2C19*2 0.0007 2 clomiprimine 0.0006 PM lower dose 0.000000402    
CYP2C19*
8 CYP2C19*8 0.0003 1 clopidogrel 0.0268 PM do not use 0.000008984    
CYP2C19*
8 CYP2C19*8 0.0003 1 voriconazole 0.0001 PM 
moniter 
serum level 0.000000034    
CYP2C19*
8 CYP2C19*8 0.0003 1 nortriptyline 0.0055 PM lower dose 0.000001844    
CYP2C19*
8 CYP2C19*8 0.0003 1 protriptyline 0.0001 PM lower dose 0.000000034    
CYP2C19*
8 CYP2C19*8 0.0003 1 desipramine 0.0004 PM lower dose 0.000000134    
CYP2C19*
8 CYP2C19*8 0.0003 1 sertraline 0.0592 PM lower dose 0.000019846    
CYP2C19*
8 CYP2C19*8 0.0003 1 doxepin 0.0041 PM lower dose 0.000001374    
CYP2C19*
8 CYP2C19*8 0.0003 1 trimipramine 0.0000 PM lower dose 0.000000002    
CYP2C19*
8 CYP2C19*8 0.0003 1 imipramine 0.0014 PM lower dose 0.000000469    
CYP2C19*
8 CYP2C19*8 0.0003 1 amitriptyline 0.0192 PM lower dose 0.000006436    
CYP2C19*
8 CYP2C19*8 0.0003 1 citalopram 0.0480 PM lower dose 0.000016091    
CYP2C19*
8 CYP2C19*8 0.0003 1 escitalopram 0.0401 PM lower dose 0.000013443    
CYP2C19*
8 CYP2C19*8 0.0003 1 clomiprimine 0.0006 PM lower dose 0.000000201    
CYP2C19*
8 CYP2C19*1 0.0027 8 clopidogrel 0.0268 IM do not use 0.000071874    
CYP2C19*
8 CYP2C19*1 0.0027 8 voriconazole 0.0001 IM 
monitor 
serum level 0.000000268    
CYP2C19*
8 CYP2C19*1 0.0027 8 phenytoin 0.0054 IM reduce dose 0.000014482    
CYP2C9*3 CYP2C9*3 0.0030 9 phenytoin 0.0054 PM reduce dose 0.000016292    
CYP2C9*3 CYP2C9*3 0.0030 9 celecoxib 0.0125 PM reduce dose 0.000037714    
CYP2C9*3 CYP2C9*1 0.0647 193 celecoxib 0.0125 IM reduce dose 0.000808750    
CYP2C9*3 CYP2C9*1 0.0647 193 phenytoin 0.0054 IM reduce dose 0.000349380    
CYP2C9*3 CYP2C9*1 0.0647 193 tacrolimus 0.0025 IM change dose 0.000161750    
DPYD 
rs67376798
A DPYD*1 0.0013 4 flourouracil 0.0022 IM 
50% dose 
reduction 0.000002950    
DPYD 
rs67376798
A DPYD*1 0.0013 4 capecitabine 0.0003 IM 
50% dose 
reduction 0.000000402    
DPYD*2A DPYD*1 0.0034 10 flourouracil 0.0022 PM 
use other 
drug 0.000007375    
DPYD*2A DPYD*1 0.0034 10 capecitabine 0.0003 PM 
use other 
drug 0.000001006    
SLCO1B1*
5 
SLCO1B1*
1 0.1861 555 simvastatin 0.0763 IM 
lower dose 
or alt 0.014195944    
SLCO1B1*
5 
SLCO1B1*
5 0.0191 57 simvastatin 0.0763 PM 
lower dose 
or alt 0.001457962    
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TPMT*2 TPMT*1 0.0050 15 azathioprine 0.0000 IM lower dose 0.000000030    
TPMT*2 TPMT*1 0.0050 15 
mercaptopuri
ne 0.0021 IM lower dose 0.000010560    
TPMT*2 TPMT*1 0.0050 15 thioguanine 0.0001 IM lower dose 0.000000302    
TPMT*2 TPMT*2 0.0003 1 azathioprine 0.0000 PM 
use other 
drug 0.000000002    
TPMT*2 TPMT*2 0.0003 1 
mercaptopuri
ne 0.0021 PM 
use other 
drug 0.000000704    
TPMT*2 TPMT*2 0.0003 1 thioguanine 0.0001 PM 
use other 
drug 0.000000020    
TPMT*3A TPMT*1 0.0178 53 thioguanine 0.0000 IM lower dose 0.000000107    
TPMT*3A TPMT*1 0.0178 53 azathioprine 0.0021 IM lower dose 0.000037311    
TPMT*3A TPMT*1 0.0178 53 
mercaptopuri
ne 0.0001 IM lower dose 0.000001066    
TPMT*3A TPMT*3A 0.0007 2 thioguanine 0.0000 PM 
use other 
drug 0.000000004    
TPMT*3A TPMT*3A 0.0007 2 azathioprine 0.0021 PM 
use other 
drug 0.000001408    
TPMT*3A TPMT*3A 0.0007 2 
mercaptopuri
ne 0.0001 PM 
use other 
drug 0.000000040    
TPMT*3A TPMT*3B 0.0251 75 thioguanine 0.0000 PM 
use alt drug 
or 90% dose 
reduce 0.000000151    
TPMT*3A TPMT*3B 0.0251 75 azathioprine 0.0021 PM 
use alt drug 
or 90% dose 
reduce 0.000052799    
TPMT*3A TPMT*3B 0.0251 75 
mercaptopuri
ne 0.0001 PM 
use alt drug 
or 90% dose 
reduce 0.000001509    
UGT1A1*6 UGT1A1*6 0.0007 2 irinotecan 0.0000 PM dose change 0.000000002    
G6PD II G6PD II 0.0030 9 rasburicase 0.0000 
10-60% 
of 
normal 
use other 
drug 0.000000000    
G6PD II G6PD II 0.0030 9 
methylene 
blue 0.0000 
10-60% 
of 
normal 
use other 
drug 0.000000001    
G6PD II G6PD III 0.0037 11 rasburicase 0.0000 
10-60% 
of 
normal 
use other 
drug 0.000000000    
G6PD II G6PD III 0.0037 11 
methylene 
blue 0.0000 
10-60% 
of 
normal 
use other 
drug 0.000000001    
G6PD III G6PD III 0.0318 95 rasburicase 0.0000 
10-60% 
of 
normal 
use other 
drug 0.000000001    
G6PD III G6PD III 0.0318 95 
methylene 
blue 0.0000 
10-60% 
of 
normal 
use other 
drug 0.000000006    
total actionable 
genotypes  1483    ARR= 0.021680452    
total observations  2983    ANNS= 46.12449929    
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